

*PBS
Expenditure
and
Prescriptions
Report
1 July 2018
to
30 June 2019*

*PBS Information Management Section
Pricing and PBS Policy Branch
Technology Assessment and Access Division*

This publication and previous editions can be accessed via the internet:
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries or feedback to:

Surface mail: Director
PBS Information Management Section
Pricing and PBS Policy Branch, MDP 900
Department of Health
GPO Box 9848 Canberra ACT 2601

E-mail: pbsstats@health.gov.au

Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health by the Department of Human Services. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by the Department of Human Services. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by the approved suppliers. Claims of manually processed PBS programs are excluded.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctor's Bag

The financial information in this publication is presented on a cash (expenditure) basis, except where indicated otherwise.

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2019, the general patient safety net threshold was **\$1,550.70**. When patients and/or their families reached this amount, they could apply for a Safety Net Card and pay only **\$6.50** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$390.00**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by the Department of Human Services. The historical data from 1948-49 to 2015-16 on pages 26 to 31 remains by date of processing.

Caution should be exercised in referring to the breakdown by patient category in Table 21(a) on pages 27 to 28 and Table 21(b) on pages 29 to 32, because of a past problem in data supplied by the Department of Human Services whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed for 2008-09, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient

category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables in this report, this data does not include supplies to Aboriginal Health Services with the exception of Tables 1(a) and 1(b) on page 1.

Expenditure on nusinersen was adjusted to include manual payments that were not processed through the PBS Online system.

The Department of Health has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

Summary of Pharmaceutical Benefits Scheme 2018-2019

Total Pharmaceutical Benefits Scheme (PBS) Government expense for the supply of medicines under Section 85 and Section 100 on an accrual accounting basis for the 2018-2019 financial year was **\$11,818 million** (excluding revenue), compared with **\$11,690 million** for the previous year. This is an increase of **1.1%**.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by date of supply financial year, however a few tables refer to Section 85 only and there are some tables that report pharmacy program expenditure.

Total 2018-19 PBS subsidised prescription volumes increased by **0.5%** to a total of **205.1 million**, compared to 204.1 million for the 2017-18 financial year.

In 2018-19, PBS Government expenditure on a cash accounting basis for the supply of medicines under Section 85 and Section 100 was **\$11,699 million** (excluding rebates) which is **88.7%** of the total cost of PBS prescriptions. The remainder was patient contributions that amounted to **\$1,485 million**.

The majority of Government expenditure in 2018-19 on PBS Section 85 and Section 100 prescriptions was directed towards concessional cardholders (**\$7,777 million, 66.5% of the total**), compared to concessional cardholders expenditure for 2017-18 (**\$7,866 million, 67.8%** of the total).

The average dispensed price (Patient payment plus Government benefit) per prescription of PBS subsidised medicines increased to **\$64.33** in 2018-19, compared to **\$64.04** in 2017-18.

There were **900** different medicines in **5,455** brands listed on the PBS as at 30 June 2019.

List of tables

Table	Description	Page
Table 1(a)	PBS Expense on an Accrual Accounting Basis, 2017-18 and 2018-19	1
Table 1(b)	PBS Section 100 Programs on an Accrual Accounting Basis, 2017-18 and 2018-19	1
Table 2(a)	PBS Prescriptions, 2017-18 and 2018-19 (incl. under co-pay prescriptions)	2
Table 2(b)	PBS Government Cost, 2017-18 and 2018-19 (excl. under co-pay prescriptions)	2
Table 2(c)	RPBS and PBS Subsidised Prescriptions for DVA patients, 2017-18 and 2018-19 (excl. under co-pay prescriptions)	2
Table 2(d)	RPBS and PBS Government Cost for DVA patients, 2017-18 and 2018-19 (excl. under co-pay prescriptions)	2
Table 3(a)	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2018-19 (excl. under co-pay prescriptions)	3
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2018-19 (excl. under co-pay prescriptions)	3
Table 3(c)	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2017-18 and 2018-19 (excl. under co-pay prescriptions)	3
Table 4	PBS Subsidised Prescriptions by Pharmacy State, 2018-19 (excl. under co-pay prescriptions)	4
Table 5(a)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2018-19 (excl. under co-pay prescriptions)	5
Table 5(b)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2018-19 (excl. under co-pay prescriptions)	6
Table 5(c)	Top 25 PBS Cancer Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2018-19 (excl. under co-pay prescriptions)	7
Table 5(d)	Top 25 PBS Biologic Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2018-19 (excl. under co-pay prescriptions)	7
Table 6	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2018-19 (incl. under co-pay prescriptions)	8
Table 7	Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2018-19 (incl. under co-pay prescriptions)	9
Table 8	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2017-18 and 2018-19 (excl. under co-pay prescriptions)	10
Table 9(a)	Top 35 Drugs Sorted by Highest Change to Government Cost, 2017-18 and 2018-19 (excl. under co-pay prescriptions)	11
Table 9(b)	Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2017-18 and 2018-19 (excl. under co-pay prescription)	12
Table 10(a)	PBS Section 85 Prescription Volume, 2015-16 to 2018-19 (incl. under co-pay prescriptions, Section 85 only)	13

Table 10(b)	PBS Section 85 expenditure, 2015-16 to 2018-19 (excl. under co-pay prescriptions, Section 85 only)	13
Table 11	PBS Prescriptions and Government Cost by Formulary, 2018-19 (incl. under co-pay prescriptions)	14
Table 12(a)	Top 20 Responsible Persons by Total Cost, 2018-19 (incl. under co-pay prescriptions)	15
Table 12(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2018-19 (incl. under co-pay prescriptions)	16
Table 12(c)	Top 20 Responsible Persons by Total PBS Prescriptions, 2018-19 (incl. under co-pay prescriptions)	17
Table 13	Number of PBS Approved Suppliers, 30 June 2019	18
Table 14	PBS Brand Premiums, 2018-19	18
Table 15(a)	PBS/RPBS prescriptions dispensed by Community Pharmacies, 2018-19	19
Table 15(b)	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2018-19	19
Table 16(a)	PBS/RPBS Continued Dispensing Medicines Prescriptions by Dispensing Pharmacy State, 2018-19 (incl. under co-pay prescriptions)	20
Table 16(b)	PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State, 2018-19 (incl. under co-pay prescriptions)	20
Supplement 1	Community Pharmacy Agreement (CPA) Expenses	
Table 17	Remuneration for Community Pharmacies and Friendly Societies, 2018-19 (excl. under co-pay prescriptions)	21
Table 18	CPA Professional Pharmacy Programs Expenditure, 2018-19	22
Table 19	Actual Costs of Major Components of CPA, 2018-19	23
Table 20	Community Services Obligation (CSO) Expenditure, 2018-19	23
Supplement 2	PBS Information Line Report, 2018-19	24
Supplement 3	National Diabetes Services Scheme (NDSS)	25
Supplement 4	Historical PBS Prescriptions and Expenditure	
Table 21(a)	Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2018-19)	27
Table 21(b)	Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2018-19)	29

Table 1(a): PBS Expense on an Accrual Accounting Basis, 2017-18 and 2018-19

Category	2017-18	Percentage of Total	2018-19	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$ 6,204,796,316	53.1%	\$ 6,005,546,698	50.8%	-\$ 199,249,618	-3.2%
Section 85 - General	\$ 1,834,103,627	15.7%	\$ 1,951,411,697	16.5%	\$ 117,308,070	6.4%
Doctors' Bag	\$ 18,205,147	0.2%	\$ 17,598,747	0.1%	-\$ 606,400	-3.3%
Section 100*	\$ 3,622,593,041	31.0%	\$ 3,833,574,825	32.4%	\$ 210,981,784	5.8%
Safety Net Cards	\$ 10,525,652	0.1%	\$ 9,841,281	0.1%	-\$ 684,371	-6.5%
Total	\$ 11,690,223,783	100.0%	\$ 11,817,973,249	100.0%	\$ 127,749,466	1.1%
Total Including Revenue**	\$ 9,331,360,544		\$ 9,576,017,986		\$ 244,657,442	2.6%

*Individual S100 programs are shown in Table 1(b).

**The basis for reporting PBS revenue has changed between 2015-16 and 2016-17, and this means that Total Including Revenue cannot be compared between 2015-16 and later years. The change in reporting PBS Revenue in 2016-17 brings this report into line with PBS revenue as reported in the Department of Health Annual Report.

Table 1(b): PBS Section 100 Programs on an Accrual Accounting Basis, 2017-18 and 2018-19

Category	2017-18	Percentage of Total	2018-19	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$ 1,820,964,882	50.3%	\$ 1,922,113,426	50.1%	\$ 101,148,544	5.6%
Chemotherapy (EFC & CPAP)	\$ 1,514,452,319	41.8%	\$ 1,611,224,630	42.0%	\$ 96,772,311	6.4%
In Vitro Fertilisation	\$ 108,511,462	3.0%	\$ 116,891,228	3.0%	\$ 8,379,766	7.7%
Opiate Dependence Treatment Program	\$ 56,249,840	1.6%	\$ 60,197,175	1.6%	\$ 3,947,335	7.0%
Aboriginal Health Services (GST exclusive)	\$ 44,087,205	1.2%	\$ 45,535,967	1.2%	\$ 1,448,762	3.3%
Botulinum Toxin Program (incl. Dysport)	\$ 50,961,818	1.4%	\$ 48,697,916	1.3%	-\$ 2,263,902	-4.4%
Human Growth Hormone	\$ 26,844,849	0.7%	\$ 28,545,885	0.7%	\$ 1,701,037	6.3%
Paraplegic and Quadriplegic Program	\$ 360,357	0.0%	\$ 209,931	0.0%	-\$ 150,425	-41.7%
Continuing Medication Program	\$ 160,310	0.0%	\$ 158,667	0.0%	-\$ 1,642	-1.0%
Total	\$ 3,622,593,041	100.0%	\$ 3,833,574,825	100.0%	\$ 210,981,784	5.8%

Note:

Expense figures refer to payments made through the Department of Human Services and directly from the Department of Health Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on www.pbs.gov.au.

Table 2(a): PBS Prescriptions, 2017-18 and 2018-19

Section 85 and S100*, including Drs Bag and under co-payment prescriptions

Patient Category	2017-18		2018-19		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	149,312,355	73.2%	149,565,438	72.9%	253,083	0.2%
Concessional Safety Net	37,147,957	18.2%	37,606,508	18.3%	458,551	1.2%
Total Concessional	186,460,312	91.4%	187,171,946	91.3%	711,634	0.4%
General Non-Safety Net	14,579,378	7.1%	14,854,016	7.2%	274,638	1.9%
General Safety Net	2,638,462	1.3%	2,659,690	1.3%	21,228	0.8%
Total General	17,217,840	8.4%	17,513,706	8.5%	295,866	1.7%
Doctors Bag	398,101	0.2%	402,827	0.2%	4,726	1.2%
Total (Over Co-payment)	204,076,253	100.0%	205,088,479	100.0%	1,012,226	0.5%
Under Co-payment	89,498,080		93,926,477		4,428,397	4.9%

Table 2(b): PBS Government Cost, 2017-18 and 2018-19

Section 85 and S100*, including Drs Bag and excluding under co-payment prescriptions

Patient Category	2017-18		2018-19		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$ 6,524,518,792	56.2%	\$ 6,417,711,929	54.9%	-\$ 106,806,863	-1.6%
Concessional Safety Net	\$ 1,342,634,855	11.6%	\$ 1,359,442,973	11.6%	\$ 16,808,118	1.3%
Total Concessional	\$ 7,867,153,647	67.8%	\$ 7,777,154,902	66.5%	-\$ 89,998,745	-1.1%
General Non-Safety Net	\$ 3,599,858,079	31.0%	\$ 3,781,994,308	32.3%	\$ 182,136,230	5.1%
General Safety Net	\$ 120,492,572	1.0%	\$ 123,566,005	1.1%	\$ 3,073,433	2.6%
Total General	\$ 3,720,350,651	32.1%	\$ 3,905,560,313	33.4%	\$ 185,209,662	5.0%
Doctors Bag	\$ 16,570,865	0.1%	\$ 16,002,440	0.1%	-\$ 568,424	-3.4%
Total (Over Co-payment)	\$ 11,604,075,163	100.0%	\$ 11,698,717,656	100.0%	\$ 94,642,493	0.8%

Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2017-18 and 2018-19

PBS Section 85 and S100* and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2017-18		2018-19		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	6,731,496	75%	6,348,189	75%	-383,307	-5.7%
Repatriation Safety Net	2,257,517	25%	2,153,072	25%	-104,445	-4.6%
Total Repatriation	8,989,013	100%	8,501,261	100%	-487,752	-5.4%

Table 2(d): RPBS and PBS Government Cost for DVA patients, 2017-18 and 2018-19

Section 85 and S100* and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2017-18		2018-19		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$ 250,746,375	77%	\$ 241,311,020	77%	-\$ 9,435,355	-3.8%
Repatriation Safety Net	\$ 72,983,156	23%	\$ 70,852,378	23%	-\$ 2,130,778	-2.9%
Total Repatriation	\$ 323,729,531	100%	\$ 312,163,398	100%	-\$ 11,566,133	-3.6%

* Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2018-19
Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2018-19	Concessional Non-Safety Net	148,244,490	\$ 4,844,366,564	\$ 929,032,414	\$ 5,773,398,978	\$ 38.95
	Concessional Safety Net	37,499,894	\$ 1,243,669,704	\$ -	\$ 1,243,669,704	\$ 33.16
	Total Concessional	185,744,384	\$ 6,088,036,267	\$ 929,032,414	\$ 7,017,068,682	\$ 37.78
	General Non-Safety Net	13,490,749	\$ 2,005,253,340	\$ 494,513,005	\$ 2,499,766,344	\$ 185.29
	General Safety Net	2,637,491	\$ 102,355,665	\$ 16,477,196	\$ 118,832,860	\$ 45.06
	Total General	16,128,240	\$ 2,107,609,004	\$ 510,990,200	\$ 2,618,599,205	\$ 162.36
	Total (excluding Drs Bag)	201,872,624	\$ 8,195,645,272	\$ 1,440,022,615	\$ 9,635,667,887	\$ 47.73
	Doctors Bag	402,827	\$ 16,002,440	\$ -	\$ 16,002,440	\$ 39.73
Total (including Drs Bag)	202,275,451	\$ 8,211,647,712	\$ 1,440,022,615	\$ 9,651,670,327	\$ 47.72	

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2018-19
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2018-19	Concessional Non-Safety Net	149,565,438	\$ 6,417,711,929	\$ 934,987,386	\$ 7,352,699,315	\$ 49.16
	Concessional Safety Net	37,606,508	\$ 1,359,442,973	\$ -	\$ 1,359,442,973	\$ 36.15
	Total Concessional	187,171,946	\$ 7,777,154,902	\$ 934,987,386	\$ 8,712,142,288	\$ 46.55
	General Non-Safety Net	14,854,016	\$ 3,781,994,308	\$ 533,093,882	\$ 4,315,088,191	\$ 290.50
	General Safety Net	2,659,690	\$ 123,566,005	\$ 16,583,651	\$ 140,149,656	\$ 52.69
	Total General	17,513,706	\$ 3,905,560,313	\$ 549,677,533	\$ 4,455,237,846	\$ 254.39
	Total (excluding Drs Bag)	204,685,652	\$ 11,682,715,215	\$ 1,484,664,919	\$ 13,167,380,134	\$ 64.33
	Doctors Bag	402,827	\$ 16,002,440	\$ -	\$ 16,002,440	\$ 39.73
Total (including Drs Bag)	205,088,479	\$ 11,698,717,656	\$ 1,484,664,919	\$ 13,183,382,575	\$ 64.28	

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2017-18 and 2018-19
Section 85 and Section 100, excluding Drs Bag and including under co-payment prescriptions

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)***	Total Cost*	Ave. Price**
2017	Jul	16,829,328	7,634,132	24,463,460	\$ 939,948,089	\$ 121,741,918	\$ 1,061,690,007	\$ 63.09
	Aug	17,888,119	7,977,877	25,865,996	\$ 1,029,920,524	\$ 120,991,673	\$ 1,150,912,197	\$ 64.34
	Sep	16,997,504	7,391,643	24,389,147	\$ 974,409,883	\$ 107,702,514	\$ 1,082,112,397	\$ 63.66
	Oct	17,610,862	7,257,485	24,868,347	\$ 1,014,247,248	\$ 104,493,539	\$ 1,118,740,786	\$ 63.53
	Nov	18,011,665	7,037,503	25,049,168	\$ 1,039,689,386	\$ 100,103,566	\$ 1,139,792,952	\$ 63.28
	Dec	19,553,386	7,006,244	26,559,630	\$ 1,057,764,040	\$ 96,333,793	\$ 1,154,097,833	\$ 59.02
2018	Jan	14,987,319	7,202,077	22,189,396	\$ 884,065,496	\$ 128,129,554	\$ 1,012,195,050	\$ 67.54
	Feb	14,884,732	6,923,134	21,807,866	\$ 858,381,448	\$ 126,709,748	\$ 985,091,197	\$ 66.18
	Mar	16,700,511	7,791,559	24,492,070	\$ 952,631,177	\$ 141,905,489	\$ 1,094,536,666	\$ 65.54
	Apr	15,935,514	7,413,981	23,349,495	\$ 892,817,795	\$ 134,031,718	\$ 1,026,849,512	\$ 64.44
	May	17,733,186	8,054,650	25,787,836	\$ 1,031,906,891	\$ 145,156,954	\$ 1,177,063,845	\$ 66.38
	Jun	16,546,026	7,807,790	24,353,816	\$ 911,722,321	\$ 128,301,567	\$ 1,040,023,887	\$ 62.86
Total		203,678,152	89,498,075	293,176,227	\$ 11,587,504,298	\$ 1,455,602,031	\$ 13,043,106,329	\$ 64.04
2018	Jul	17,270,148	8,041,862	25,312,010	\$ 985,189,464	\$ 126,661,554	\$ 1,111,851,018	\$ 64.38
	Aug	17,867,165	8,204,410	26,071,575	\$ 988,003,202	\$ 122,527,616	\$ 1,110,530,819	\$ 62.15
	Sep	16,557,429	7,564,931	24,122,360	\$ 915,809,546	\$ 107,279,439	\$ 1,023,088,985	\$ 61.79
	Oct	18,236,219	7,837,763	26,073,982	\$ 1,025,144,081	\$ 109,413,206	\$ 1,134,557,287	\$ 62.21
	Nov	18,232,265	7,549,779	25,782,044	\$ 1,035,016,877	\$ 102,811,433	\$ 1,137,828,310	\$ 62.41
	Dec	19,620,891	7,432,485	27,053,376	\$ 1,056,565,640	\$ 98,038,646	\$ 1,154,604,286	\$ 58.85
2019	Jan	15,090,250	7,593,570	22,683,820	\$ 898,147,227	\$ 130,765,979	\$ 1,028,913,205	\$ 68.18
	Feb	15,028,816	7,320,807	22,349,623	\$ 882,393,578	\$ 129,867,308	\$ 1,012,260,886	\$ 67.35
	Mar	16,417,711	8,066,808	24,484,519	\$ 961,840,697	\$ 141,652,904	\$ 1,103,493,601	\$ 67.21
	Apr	16,323,648	7,880,578	24,204,226	\$ 937,983,973	\$ 138,683,782	\$ 1,076,667,755	\$ 65.96
	May	17,783,329	8,412,617	26,195,946	\$ 1,053,463,256	\$ 147,130,450	\$ 1,200,593,707	\$ 67.51
	Jun	16,257,781	8,020,865	24,278,646	\$ 943,157,674	\$ 129,832,601	\$ 1,072,990,275	\$ 66.00
Total		204,685,652	93,926,475	298,612,127	\$ 11,682,715,215	\$ 1,484,664,919	\$ 13,167,380,134	\$ 64.33

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution reported in table 3(b) in the 2017-18 report included under co-payment prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2018-19

Section 85 and Section 100[^], excluding Drs Bag and excluding under co-payment prescriptions

PBS S85 subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	48,337,492	37,191,893	30,337,116	12,600,214	13,416,820	4,293,400	537,261	1,530,294	148,244,490
Concessional Safety Net	13,246,566	9,135,558	7,473,460	3,105,578	3,048,510	1,071,549	59,122	359,551	37,499,894
General Non-Safety Net	4,458,085	3,141,701	2,780,545	903,108	1,494,566	296,570	128,544	287,630	13,490,749
General Safety Net	929,974	629,828	473,002	187,513	290,159	49,867	7,867	69,281	2,637,491
Total	66,972,117	50,098,980	41,064,123	16,796,413	18,250,055	5,711,386	732,794	2,246,756	201,872,624
PBS (S85 + S100) subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	48,735,756	37,534,932	30,616,586	12,704,448	13,543,507	4,325,777	546,852	1,557,580	149,565,438
Concessional Safety Net	13,275,558	9,169,246	7,496,415	3,113,202	3,057,605	1,074,267	59,316	360,899	37,606,508
General Non-Safety Net	4,907,808	3,486,730	3,022,062	992,171	1,639,280	318,213	142,120	345,632	14,854,016
General Safety Net	933,865	638,825	478,823	188,386	292,210	50,041	7,880	69,660	2,659,690
Total	67,852,987	50,829,733	41,613,886	16,998,207	18,532,602	5,768,298	756,168	2,333,771	204,685,652
Government Cost (S85 only)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 1,604,167,553	\$ 1,191,618,954	\$ 997,745,891	\$ 398,123,781	\$ 440,150,382	\$ 139,502,916	\$ 16,528,433	\$ 56,528,653	\$ 4,844,366,564
Concessional Safety Net	\$ 438,992,462	\$ 301,146,500	\$ 246,850,297	\$ 101,445,195	\$ 103,555,616	\$ 37,064,247	\$ 1,794,839	\$ 12,820,548	\$ 1,243,669,704
General Non-Safety Net	\$ 638,031,126	\$ 533,491,797	\$ 373,134,059	\$ 134,110,694	\$ 219,453,897	\$ 48,739,134	\$ 14,486,833	\$ 43,805,799	\$ 2,005,253,340
General Safety Net	\$ 35,970,101	\$ 24,707,945	\$ 17,328,032	\$ 7,268,699	\$ 12,029,972	\$ 1,983,275	\$ 247,608	\$ 2,820,033	\$ 102,355,665
Total	\$ 2,717,161,243	\$ 2,050,965,196	\$ 1,635,058,279	\$ 640,948,368	\$ 775,189,867	\$ 227,289,573	\$ 33,057,714	\$ 115,975,033	\$ 8,195,645,272
Government Cost (S85 + S100)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 2,074,363,119	\$ 1,577,289,609	\$ 1,352,445,998	\$ 531,581,906	\$ 594,001,865	\$ 185,263,339	\$ 25,354,355	\$ 77,411,737	\$ 6,417,711,929
Concessional Safety Net	\$ 467,961,603	\$ 334,828,454	\$ 273,680,582	\$ 112,060,705	\$ 113,407,887	\$ 41,423,996	\$ 2,014,338	\$ 14,065,409	\$ 1,359,442,973
General Non-Safety Net	\$ 1,248,653,963	\$ 961,698,878	\$ 696,701,729	\$ 249,695,100	\$ 420,254,769	\$ 81,789,633	\$ 32,152,244	\$ 91,047,993	\$ 3,781,994,308
General Safety Net	\$ 40,467,747	\$ 31,759,305	\$ 22,966,549	\$ 8,301,778	\$ 14,346,666	\$ 2,210,994	\$ 264,899	\$ 3,248,068	\$ 123,566,005
Total	\$ 3,831,446,432	\$ 2,905,576,246	\$ 2,345,794,858	\$ 901,639,490	\$ 1,142,011,186	\$ 310,687,961	\$ 59,785,835	\$ 185,773,207	\$ 11,682,715,215
Total Cost (S85 + S100)*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 2,377,245,682	\$ 1,817,094,213	\$ 1,541,423,476	\$ 611,345,270	\$ 678,020,895	\$ 212,193,922	\$ 28,088,938	\$ 87,286,918	\$ 7,352,699,315
Concessional Safety Net	\$ 467,961,603	\$ 334,828,454	\$ 273,680,582	\$ 112,060,705	\$ 113,407,887	\$ 41,423,996	\$ 2,014,338	\$ 14,065,409	\$ 1,359,442,973
General Non-Safety Net	\$ 1,421,662,245	\$ 1,094,656,404	\$ 800,875,391	\$ 285,440,520	\$ 479,390,641	\$ 92,883,621	\$ 36,039,271	\$ 104,140,099	\$ 4,315,088,191
General Safety Net	\$ 46,266,615	\$ 35,810,611	\$ 25,924,863	\$ 9,477,303	\$ 16,155,556	\$ 2,515,767	\$ 309,877	\$ 3,689,063	\$ 140,149,656
Total	\$ 4,313,136,145	\$ 3,282,389,682	\$ 2,641,904,313	\$ 1,018,323,798	\$ 1,286,974,979	\$ 349,017,306	\$ 66,452,424	\$ 209,181,489	\$ 13,167,380,134
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population**	8,046,070	6,526,413	5,052,827	1,742,744	2,606,338	531,529	245,854	423,811	25,180,234
PBS S85 Subsidised Scripts per Capita	8.32	7.68	8.13	9.64	7.00	10.75	2.98	5.30	8.02
PBS (S85 + S100) Subsidised Scripts per Capita	8.43	7.79	8.24	9.75	7.11	10.85	3.08	5.51	8.13
PBS S85 Govt Cost per Capita	\$ 337.70	\$ 314.26	\$ 323.59	\$ 367.78	\$ 297.42	\$ 427.61	\$ 134.46	\$ 273.65	\$ 325.48
PBS (S85 + S100) Govt Cost per Capita	\$ 476.19	\$ 445.20	\$ 464.25	\$ 517.37	\$ 438.17	\$ 584.52	\$ 243.18	\$ 438.34	\$ 463.96
Population Percentage	31.95%	25.92%	20.07%	6.92%	10.35%	2.11%	0.98%	1.68%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	33.15%	24.83%	20.33%	8.30%	9.05%	2.82%	0.37%	1.14%	100.00%
PBS (S85 + S100) Govt Cost Percentage	32.80%	24.87%	20.08%	7.72%	9.78%	2.66%	0.51%	1.59%	100.00%
Total Cost Percentage	32.76%	24.93%	20.06%	7.73%	9.77%	2.65%	0.50%	1.59%	100.00%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

**Population 31 December 2018, Source: ABS Publication 3101.04

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(a): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2018-19
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	SOFOSBUVIR + VELPATASVIR	25,427	\$ 390,702,145	\$ 526,360	\$ 391,228,505	\$ 15,386.34
2	AFLIBERCEPT	273,387	\$ 338,561,125	\$ 4,084,496	\$ 342,645,621	\$ 1,253.34
3	ADALIMUMAB	244,506	\$ 315,230,464	\$ 6,719,813	\$ 321,950,277	\$ 1,316.74
4	NIVOLUMAB	52,215	\$ 258,796,640	\$ 207,176	\$ 259,003,816	\$ 4,960.33
5	PEMBROLIZUMAB	24,810	\$ 212,942,681	\$ 116,610	\$ 213,059,291	\$ 8,587.64
6	DENOSUMAB	759,525	\$ 211,437,708	\$ 8,968,119	\$ 220,405,827	\$ 290.19
7	RANIBIZUMAB	167,615	\$ 192,018,992	\$ 2,211,545	\$ 194,230,537	\$ 1,158.79
8	USTEKINUMAB	25,556	\$ 177,539,808	\$ 759,620	\$ 178,299,428	\$ 6,976.81
9	GLECAPREVIR + PIBRENTASVIR	9,193	\$ 173,347,521	\$ 213,712	\$ 173,561,233	\$ 18,879.72
10	TRASTUZUMAB	58,973	\$ 163,796,241	\$ 636,475	\$ 164,432,716	\$ 2,788.27
11	APIXABAN	2,000,103	\$ 162,331,236	\$ 23,258,998	\$ 185,590,234	\$ 92.79
12	LENALIDOMIDE	23,780	\$ 144,816,000	\$ 369,680	\$ 145,185,680	\$ 6,105.37
13	RIVAROXABAN	1,898,852	\$ 140,061,915	\$ 26,232,215	\$ 166,294,130	\$ 87.58
14	FINGOLIMOD	60,669	\$ 132,384,671	\$ 1,661,324	\$ 134,045,995	\$ 2,209.46
15	IBRUTINIB	13,556	\$ 125,939,876	\$ 199,570	\$ 126,139,446	\$ 9,305.06
16	INFLIXIMAB	57,023	\$ 116,455,657	\$ 1,835,611	\$ 118,291,268	\$ 2,074.45
17	PREGABALIN	3,526,990	\$ 109,761,713	\$ 28,638,641	\$ 138,400,354	\$ 39.24
18	ETANERCEPT	103,181	\$ 105,721,523	\$ 2,402,809	\$ 108,124,332	\$ 1,047.91
19	OCRELIZUMAB	6,202	\$ 105,039,805	\$ 195,312	\$ 105,235,117	\$ 16,967.93
20	LUMACAFTOR + IVACAFTOR	5,595	\$ 104,787,685	\$ 75,178	\$ 104,862,863	\$ 18,742.25
21	RITUXIMAB	41,085	\$ 103,526,606	\$ 338,848	\$ 103,865,454	\$ 2,528.06
22	ENZALUTAMIDE	26,728	\$ 99,368,482	\$ 308,760	\$ 99,677,242	\$ 3,729.32
23	INSULIN GLARGINE	383,734	\$ 94,410,007	\$ 5,568,636	\$ 99,978,643	\$ 260.54
24	FLUTICASON + SALMETEROL	2,322,143	\$ 92,630,937	\$ 39,558,487	\$ 132,189,424	\$ 56.93
25	ROSUVASTATIN	7,292,825	\$ 89,291,516	\$ 38,881,763	\$ 128,173,279	\$ 17.58
26	ESOMEPRAZOLE	6,221,865	\$ 88,773,420	\$ 31,642,068	\$ 120,415,488	\$ 19.35
27	IPILIMUMAB	2,854	\$ 81,646,006	\$ 33,748	\$ 81,679,754	\$ 28,619.40
28	BEVACIZUMAB	35,833	\$ 80,195,448	\$ 152,047	\$ 80,347,494	\$ 2,242.28
29	FERRIC CARBOXYMALTOSE	289,042	\$ 79,397,460	\$ 7,121,112	\$ 86,518,572	\$ 299.33
30	GOLIMUMAB	58,699	\$ 75,749,793	\$ 1,534,188	\$ 77,283,981	\$ 1,316.61
31	MESALAZINE	340,547	\$ 75,476,107	\$ 9,347,760	\$ 84,823,868	\$ 249.08
32	SECUKINUMAB	45,221	\$ 69,625,480	\$ 1,248,955	\$ 70,874,435	\$ 1,567.29
33	PEGFILGRASTIM	58,122	\$ 68,830,618	\$ 1,598,175	\$ 70,428,793	\$ 1,211.74
34	RIBOCICLIB	13,241	\$ 67,906,202	\$ 286,197	\$ 68,192,399	\$ 5,150.09
35	NUSINERSEN	583	\$ 67,639,822	\$ 10,178	\$ 67,650,000	\$ 116,037.74
36	PALIPERIDONE	211,236	\$ 67,358,018	\$ 2,197,509	\$ 69,555,527	\$ 329.28
37	OXYCODONE + NALOXONE	1,741,384	\$ 67,280,684	\$ 12,552,592	\$ 79,833,276	\$ 45.84
38	TIOTROPIUM	1,537,218	\$ 66,784,273	\$ 14,028,831	\$ 80,813,104	\$ 52.57
39	ATORVASTATIN	7,388,219	\$ 65,829,038	\$ 38,312,088	\$ 104,141,126	\$ 14.10
40	IVACAFTOR	2,890	\$ 65,246,717	\$ 47,219	\$ 65,293,937	\$ 22,593.06
41	TOFACITINIB	50,119	\$ 62,519,401	\$ 1,003,489	\$ 63,522,889	\$ 1,267.44
42	DARBEPOETIN ALFA	62,767	\$ 62,116,447	\$ 842,681	\$ 62,959,128	\$ 1,003.06
43	BUDESONIDE + FORMOTEROL (EFOMOTEROL)	1,772,349	\$ 61,564,808	\$ 33,268,618	\$ 94,833,426	\$ 53.51
44	ARIPIPRAZOLE	326,115	\$ 59,522,197	\$ 4,122,801	\$ 63,644,998	\$ 195.16
45	LEVODOPA + CARBIDOPA	272,601	\$ 59,041,741	\$ 1,813,094	\$ 60,854,835	\$ 223.24
46	SITAGLIPTIN + METFORMIN	1,394,794	\$ 57,607,511	\$ 23,507,469	\$ 81,114,980	\$ 58.16
47	RUXOLITINIB	11,524	\$ 57,114,932	\$ 178,475	\$ 57,293,407	\$ 4,971.66
48	GOSERELIN	96,866	\$ 55,441,375	\$ 2,058,085	\$ 57,499,459	\$ 593.60
49	BORTEZOMIB	39,640	\$ 53,540,076	\$ 77,001	\$ 53,617,077	\$ 1,352.60
50	TRAMETINIB	5,999	\$ 53,240,337	\$ 119,942	\$ 53,360,278	\$ 8,894.86

* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(b): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2018-19
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	ATORVASTATIN	7,388,219	\$ 65,829,038	\$ 38,312,088	\$ 104,141,126	\$ 14.10
2	ROSUVASTATIN	7,292,825	\$ 89,291,516	\$ 38,881,763	\$ 128,173,279	\$ 17.58
3	ESOMEPRAZOLE	6,221,865	\$ 88,773,420	\$ 31,642,068	\$ 120,415,488	\$ 19.35
4	PANTOPRAZOLE	4,999,967	\$ 46,314,333	\$ 25,099,114	\$ 71,413,446	\$ 14.28
5	PERINDOPRIL	3,920,984	\$ 35,649,091	\$ 20,878,095	\$ 56,527,187	\$ 14.42
6	PREGABALIN	3,526,990	\$ 109,761,713	\$ 28,638,641	\$ 138,400,354	\$ 39.24
7	METFORMIN	3,230,743	\$ 33,791,017	\$ 15,491,946	\$ 49,282,963	\$ 15.25
8	SALBUTAMOL	2,826,546	\$ 41,968,376	\$ 12,168,082	\$ 54,136,458	\$ 19.15
9	CEFALEXIN	2,678,081	\$ 22,253,039	\$ 14,364,338	\$ 36,617,378	\$ 13.67
10	IRBESARTAN	2,662,376	\$ 22,655,042	\$ 14,094,743	\$ 36,749,784	\$ 13.80
11	AMLODIPINE	2,510,219	\$ 18,322,082	\$ 12,976,489	\$ 31,298,571	\$ 12.47
12	FLUTICASON + SALMETEROL	2,322,143	\$ 92,630,937	\$ 39,558,487	\$ 132,189,424	\$ 56.93
13	PARACETAMOL + CODEINE	2,317,263	\$ 27,866,933	\$ 11,788,034	\$ 39,654,967	\$ 17.11
14	ATENOLOL	2,216,912	\$ 17,378,126	\$ 11,361,571	\$ 28,739,697	\$ 12.96
15	OXYCODONE	2,144,759	\$ 48,992,767	\$ 12,204,196	\$ 61,196,964	\$ 28.53
16	TELMISARTAN	2,141,254	\$ 19,467,833	\$ 11,687,766	\$ 31,155,599	\$ 14.55
17	RAMIPRIL	2,077,316	\$ 17,527,319	\$ 10,748,498	\$ 28,275,817	\$ 13.61
18	CANDESARTAN	2,070,338	\$ 18,328,883	\$ 11,121,378	\$ 29,450,261	\$ 14.22
19	SERTRALINE	2,026,922	\$ 16,696,693	\$ 10,929,070	\$ 27,625,763	\$ 13.63
20	AMOXICILLIN + CLAVULANIC ACID	2,024,406	\$ 18,522,956	\$ 10,791,017	\$ 29,313,974	\$ 14.48
21	AMOXICILLIN	2,016,916	\$ 16,912,591	\$ 11,257,192	\$ 28,169,783	\$ 13.97
22	APIXABAN	2,000,103	\$ 162,331,236	\$ 23,258,998	\$ 185,590,234	\$ 92.79
23	ESCITALOPRAM	1,935,627	\$ 16,389,464	\$ 10,609,513	\$ 26,998,978	\$ 13.95
24	SIMVASTATIN	1,920,363	\$ 15,697,416	\$ 9,890,656	\$ 25,588,072	\$ 13.32
25	RIVAROXABAN	1,898,852	\$ 140,061,915	\$ 26,232,215	\$ 166,294,130	\$ 87.58
26	MIRTAZAPINE	1,891,830	\$ 20,082,793	\$ 9,430,727	\$ 29,513,521	\$ 15.60
27	TRAMADOL	1,805,203	\$ 23,302,591	\$ 8,502,265	\$ 31,804,857	\$ 17.62
28	CLOPIDOGREL	1,775,870	\$ 18,828,971	\$ 8,434,043	\$ 27,263,015	\$ 15.35
29	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,772,349	\$ 61,564,808	\$ 33,268,618	\$ 94,833,426	\$ 53.51
30	OXYCODONE + NALOXONE	1,741,384	\$ 67,280,684	\$ 12,552,592	\$ 79,833,276	\$ 45.84
31	METOPROLOL TARTRATE	1,718,560	\$ 14,440,237	\$ 8,327,501	\$ 22,767,738	\$ 13.25
32	RABEPRAZOLE	1,691,281	\$ 16,776,194	\$ 8,605,548	\$ 25,381,743	\$ 15.01
33	VENLAFAXINE	1,684,569	\$ 18,720,170	\$ 8,971,318	\$ 27,691,488	\$ 16.44
34	DIAZEPAM	1,641,495	\$ 12,178,251	\$ 8,282,628	\$ 20,460,879	\$ 12.46
35	LERCANIDIPINE	1,622,178	\$ 14,769,637	\$ 8,206,900	\$ 22,976,537	\$ 14.16
36	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,591,434	\$ 15,106,604	\$ 8,524,923	\$ 23,631,526	\$ 14.85
37	AMITRIPTYLINE	1,556,818	\$ 14,808,112	\$ 7,577,989	\$ 22,386,101	\$ 14.38
38	TIOTROPIUM	1,537,218	\$ 66,784,273	\$ 14,028,831	\$ 80,813,104	\$ 52.57
39	PARACETAMOL	1,536,281	\$ 21,233,538	\$ 6,124,818	\$ 27,358,357	\$ 17.81
40	FUROSEMIDE (FRUSEMIDE)	1,453,417	\$ 12,587,079	\$ 6,393,416	\$ 18,980,494	\$ 13.06
41	OMEPRAZOLE	1,405,709	\$ 16,567,493	\$ 7,119,839	\$ 23,687,332	\$ 16.85
42	SITAGLIPTIN + METFORMIN	1,394,794	\$ 57,607,511	\$ 23,507,469	\$ 81,114,980	\$ 58.16
43	PERINDOPRIL + AMLODIPINE	1,370,167	\$ 14,759,108	\$ 7,649,762	\$ 22,408,870	\$ 16.35
44	MELOXICAM	1,364,117	\$ 13,344,887	\$ 7,077,550	\$ 20,422,437	\$ 14.97
45	GLICLAZIDE	1,345,980	\$ 18,448,844	\$ 6,138,549	\$ 24,587,393	\$ 18.27
46	TEMAZEPAM	1,299,452	\$ 9,825,648	\$ 6,254,173	\$ 16,079,821	\$ 12.37
47	PREDNISOLONE	1,284,530	\$ 12,166,690	\$ 6,279,684	\$ 18,446,375	\$ 14.36
48	EZETIMIBE	1,266,341	\$ 38,516,852	\$ 15,895,961	\$ 54,412,813	\$ 42.97
49	WARFARIN	1,245,242	\$ 14,510,385	\$ 5,706,685	\$ 20,217,070	\$ 16.24
50	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	1,224,648	\$ 18,394,051	\$ 5,486,604	\$ 23,880,655	\$ 19.50

* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(c): Top 25 PBS Cancer Drugs[^] (by Active Ingredient) Sorted by Highest Government Cost, 2018-19
 Section 85 and Section 100^{^^}, excluding under co-payment prescriptions, including Drs Bag

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	NIVOLUMAB	52,215	\$ 258,796,640	\$ 207,176	\$ 259,003,816	\$ 4,960.33
2	PEMBROLIZUMAB	24,810	\$ 212,942,681	\$ 116,610	\$ 213,059,291	\$ 8,587.64
3	TRASTUZUMAB	58,973	\$ 163,796,241	\$ 636,475	\$ 164,432,716	\$ 2,788.27
4	LENALIDOMIDE	23,780	\$ 144,816,000	\$ 369,680	\$ 145,185,680	\$ 6,105.37
5	IBRUTINIB	13,556	\$ 125,939,876	\$ 199,570	\$ 126,139,446	\$ 9,305.06
6	ENZALUTAMIDE	26,728	\$ 99,368,482	\$ 308,760	\$ 99,677,242	\$ 3,729.32
7	RITUXIMAB ^{^^^}	37,282	\$ 90,832,989	\$ 251,118	\$ 91,084,107	\$ 2,443.11
8	IPILIMUMAB	2,854	\$ 81,646,006	\$ 33,748	\$ 81,679,754	\$ 28,619.40
9	BEVACIZUMAB	35,833	\$ 80,195,448	\$ 152,047	\$ 80,347,494	\$ 2,242.28
10	RIBOCICLIB	13,241	\$ 67,906,202	\$ 286,197	\$ 68,192,399	\$ 5,150.09
11	RUXOLITINIB	11,524	\$ 57,114,932	\$ 178,475	\$ 57,293,407	\$ 4,971.66
12	GOSERELIN ^{^^^}	96,866	\$ 55,441,375	\$ 2,058,085	\$ 57,499,459	\$ 593.60
13	BORTEZOMIB	39,640	\$ 53,540,076	\$ 77,011	\$ 53,617,087	\$ 1,352.60
14	TRAMETINIB	5,999	\$ 53,240,337	\$ 119,942	\$ 53,360,278	\$ 8,894.86
15	CARFILZOMIB	22,518	\$ 52,434,776	\$ 30,976	\$ 52,465,752	\$ 2,329.95
16	DABRAFENIB	5,901	\$ 51,510,509	\$ 118,356	\$ 51,628,866	\$ 8,749.17
17	IMATINIB	26,001	\$ 50,543,806	\$ 538,306	\$ 51,082,112	\$ 1,964.62
18	PERTUZUMAB	15,193	\$ 50,155,071	\$ 112,900	\$ 50,267,972	\$ 3,308.63
19	DASATINIB	11,341	\$ 49,661,223	\$ 293,701	\$ 49,954,924	\$ 4,404.81
20	ABIRATERONE	13,453	\$ 48,147,304	\$ 152,083	\$ 48,299,387	\$ 3,590.23
21	LEUPRORELIN ^{^^^}	42,849	\$ 44,163,548	\$ 533,779	\$ 44,697,328	\$ 1,043.14
22	NILOTINIB	7,722	\$ 33,862,439	\$ 183,720	\$ 34,046,159	\$ 4,408.98
23	OCTREOTIDE ^{^^^}	9,665	\$ 32,758,720	\$ 200,773	\$ 32,959,493	\$ 3,410.19
24	CETUXIMAB	15,279	\$ 32,400,601	\$ 85,024	\$ 32,485,624	\$ 2,126.16
25	ATEZOLIZUMAB	3,941	\$ 30,045,314	\$ 24,207	\$ 30,069,521	\$ 7,629.92

* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes cancer supportive drugs.

^{^^} Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

^{^^^} Excludes PBS items that are not for cancer treatment.

^{^^^} Some of the usage may be for treating other conditions.

Table 5(d): Top 25 PBS Biological Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2018-19
 Section 85 and Section 100[^], excluding under co-payment prescriptions, including Drs Bag

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	273,387	\$ 338,561,125	\$ 4,084,496	\$ 342,645,621	\$ 1,253.34
2	ADALIMUMAB	244,506	\$ 315,230,464	\$ 6,719,813	\$ 321,950,277	\$ 1,316.74
3	NIVOLUMAB	52,215	\$ 258,796,640	\$ 207,176	\$ 259,003,816	\$ 4,960.33
4	PEMBROLIZUMAB	24,810	\$ 212,942,681	\$ 116,610	\$ 213,059,291	\$ 8,587.64
5	DENOSUMAB	759,525	\$ 211,437,708	\$ 8,968,119	\$ 220,405,827	\$ 290.19
6	RANIBIZUMAB	167,615	\$ 192,018,992	\$ 2,211,545	\$ 194,230,537	\$ 1,158.79
7	USTEKINUMAB	25,556	\$ 177,539,808	\$ 759,620	\$ 178,299,428	\$ 6,976.81
8	TRASTUZUMAB	58,973	\$ 163,796,241	\$ 636,475	\$ 164,432,716	\$ 2,788.27
9	INFLIXIMAB	57,023	\$ 116,455,657	\$ 1,835,611	\$ 118,291,268	\$ 2,074.45
10	ETANERCEPT	103,181	\$ 105,721,523	\$ 2,402,809	\$ 108,124,332	\$ 1,047.91
11	OCRELIZUMAB	6,202	\$ 105,039,805	\$ 195,312	\$ 105,235,117	\$ 16,967.93
12	RITUXIMAB	41,085	\$ 103,526,606	\$ 338,848	\$ 103,865,454	\$ 2,528.06
13	INSULIN GLARGINE	383,734	\$ 94,410,007	\$ 5,568,637	\$ 99,978,644	\$ 260.54
14	IPILIMUMAB	2,854	\$ 81,646,006	\$ 33,748	\$ 81,679,754	\$ 28,619.40
15	BEVACIZUMAB	35,833	\$ 80,195,448	\$ 152,047	\$ 80,347,494	\$ 2,242.28
16	GOLIMUMAB	58,699	\$ 75,749,793	\$ 1,534,188	\$ 77,283,981	\$ 1,316.61
17	SECUKINUMAB	45,221	\$ 69,625,480	\$ 1,248,955	\$ 70,874,435	\$ 1,567.29
18	PEGFILGRASTIM	58,122	\$ 68,830,618	\$ 1,598,175	\$ 70,428,793	\$ 1,211.74
19	DARBEPOETIN ALFA	62,767	\$ 62,116,447	\$ 842,681	\$ 62,959,128	\$ 1,003.06
20	VEDOLIZUMAB	16,268	\$ 50,389,492	\$ 518,535	\$ 50,908,027	\$ 3,129.34
21	PERTUZUMAB	15,193	\$ 50,155,071	\$ 112,900	\$ 50,267,972	\$ 3,308.63
22	INSULIN ASPART	281,281	\$ 50,113,667	\$ 5,407,978	\$ 55,521,645	\$ 197.39
23	FOLLITROPIN ALFA	43,276	\$ 49,883,207	\$ 1,649,084	\$ 51,532,291	\$ 1,190.78
24	ECULIZUMAB	946	\$ 43,494,316	\$ 25,481	\$ 43,519,797	\$ 46,004.01
25	NATALIZUMAB	28,088	\$ 40,162,697	\$ 849,018	\$ 41,011,715	\$ 1,460.12

* Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 6: Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2018-19
 Section 85 and Section 100[^], including Drs Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Total Government Cost
1	ROSUVASTATIN	7,292,825	4,506,057	11,798,882	\$ 128,173,279
2	ATORVASTATIN	7,388,219	3,331,877	10,720,096	\$ 104,141,126
3	ESOMEPRAZOLE	6,221,865	2,807,032	9,028,897	\$ 120,415,488
4	PANTOPRAZOLE	4,999,967	2,167,037	7,167,004	\$ 71,413,446
5	PERINDOPRIL	3,920,984	2,492,753	6,413,737	\$ 56,527,187
6	CEFALEXIN	2,678,081	2,859,106	5,537,187	\$ 36,617,378
7	AMOXICILLIN	2,016,916	3,202,240	5,219,156	\$ 28,169,783
8	METFORMIN	3,230,743	1,704,704	4,935,447	\$ 49,282,963
9	AMOXICILLIN + CLAVULANIC ACID	2,024,406	2,626,887	4,651,293	\$ 29,313,974
10	ESCITALOPRAM	1,935,627	2,516,726	4,452,353	\$ 26,998,978
11	SERTRALINE	2,026,922	2,250,902	4,277,824	\$ 27,625,763
12	PREGABALIN	3,526,990	476,560	4,003,550	\$ 138,400,354
13	IRBESARTAN	2,662,376	1,338,698	4,001,074	\$ 36,749,784
14	PARACETAMOL + CODEINE	2,317,263	1,634,995	3,952,258	\$ 39,654,967
15	TELMISARTAN	2,141,254	1,517,438	3,658,692	\$ 31,155,599
16	AMLODIPINE	2,510,219	1,136,839	3,647,058	\$ 31,298,571
17	SALBUTAMOL	2,826,546	742,751	3,569,297	\$ 54,136,458
18	CANDESARTAN	2,070,338	1,237,936	3,308,274	\$ 29,450,261
19	OXYCODONE	2,144,759	1,136,705	3,281,464	\$ 61,196,964
20	RAMIPRIL	2,077,316	1,140,703	3,218,019	\$ 28,275,817
21	ATENOLOL	2,216,912	886,688	3,103,600	\$ 28,739,697
22	VENLAFAXINE	1,684,569	1,376,351	3,060,920	\$ 27,691,488
23	TRAMADOL	1,805,203	819,361	2,624,564	\$ 31,804,857
24	MIRTAZAPINE	1,891,830	700,558	2,592,388	\$ 29,513,521
25	RABEPRAZOLE	1,691,281	859,324	2,550,605	\$ 25,381,743
26	PERINDOPRIL + AMLODIPINE	1,370,167	1,119,734	2,489,901	\$ 22,408,870
27	DIAZEPAM	1,641,495	817,048	2,458,543	\$ 20,460,879
28	SIMVASTATIN	1,920,363	534,273	2,454,636	\$ 25,588,072
29	MELOXICAM	1,364,117	1,076,552	2,440,669	\$ 20,422,437
30	AMITRIPTYLINE	1,556,818	817,234	2,374,052	\$ 22,386,101
31	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,591,434	778,263	2,369,697	\$ 23,631,526
32	FLUTICASONE + SALMETEROL	2,322,143	547	2,322,690	\$ 132,189,424
33	PREDNISOLONE	1,284,530	1,024,486	2,309,016	\$ 18,446,375
34	DOXYCYCLINE	1,079,957	1,219,543	2,299,500	\$ 14,793,047
35	METOPROLOL TARTRATE	1,718,560	554,974	2,273,534	\$ 22,767,738
36	DESVENLAFAXINE	1,184,137	1,028,794	2,212,931	\$ 33,482,622
37	CLOPIDOGREL	1,775,870	411,883	2,187,753	\$ 27,263,015
38	LERCANIDIPINE	1,622,178	553,932	2,176,110	\$ 22,976,537
39	FLUOXETINE	979,432	1,085,817	2,065,249	\$ 17,853,874
40	OXYCODONE + NALOXONE	1,741,384	319,248	2,060,632	\$ 79,833,276
41	APIXABAN	2,000,103	532	2,000,635	\$ 185,590,234
42	OMEPRAZOLE	1,405,709	592,355	1,998,064	\$ 23,687,332
43	LEVONORGESTREL + ETHINYLESTRADIOL	382,826	1,522,710	1,905,536	\$ 6,744,352
44	RIVAROXABAN	1,898,852	1,418	1,900,270	\$ 166,294,130
45	TEMAZEPAM	1,299,452	543,514	1,842,966	\$ 16,079,821
46	GLICLAZIDE	1,345,980	475,259	1,821,239	\$ 24,587,393
47	LEVOTHYROXINE	992,089	806,410	1,798,499	\$ 26,076,039
48	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,772,349	8,958	1,781,307	\$ 94,833,426
49	DULOXETINE	1,019,192	725,754	1,744,946	\$ 18,774,779
50	CITALOPRAM	946,083	767,540	1,713,623	\$ 12,488,886

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 7: Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2018-19
 Section 85 and Section 100[^], including Drs Bag and under co-payment prescriptions

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	22,917,657	14,128,134	37,045,791
2	C10	LIPID MODIFYING AGENTS	21,935,453	9,213,029	31,148,482
3	N06	PSYCHOANALEPTICS	16,542,611	12,570,192	29,112,803
4	J01	ANTIBACTERIALS FOR SYSTEMIC USE	11,638,968	14,071,070	25,710,038
5	A02	DRUGS FOR ACID RELATED DISORDERS	15,770,232	7,052,476	22,822,708
6	N02	ANALGESICS	16,813,290	5,792,105	22,605,395
7	A10	DRUGS USED IN DIABETES	11,733,512	2,276,519	14,010,031
8	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	11,457,202	1,374,646	12,831,848
9	B01	ANTITHROMBOTIC AGENTS	8,893,341	985,713	9,879,054
10	N05	PSYCHOLEPTICS	7,598,861	2,001,772	9,600,633
11	C08	CALCIUM CHANNEL BLOCKERS	6,202,657	2,388,483	8,591,140
12	C07	BETA BLOCKING AGENTS	6,310,135	2,222,812	8,532,947
13	S01	OPHTHALMOLOGICALS	6,707,721	1,578,212	8,285,933
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,614,484	3,211,966	6,826,450
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,223,149	3,350,449	5,573,598
16	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,239,082	1,958,661	4,197,743
17	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,252,624	1,641,342	3,893,966
18	C01	CARDIAC THERAPY	2,854,665	538,819	3,393,484
19	N03	ANTIEPILEPTICS	2,206,982	705,103	2,912,085
20	C03	DIURETICS	2,350,864	524,144	2,875,008
21	C02	ANTIHYPERTENSIVES	1,676,257	528,062	2,204,319
22	M05	DRUGS FOR TREATMENT OF BONE DISEASES	1,815,324	200,714	2,016,038
23	M04	ANTIGOUT PREPARATIONS	1,203,108	786,467	1,989,575
24	H03	THYROID THERAPY	1,089,454	860,776	1,950,230
25	G04	UROLOGICALS	1,560,172	334,163	1,894,335
26	L01	ANTINEOPLASTIC AGENTS	1,729,225	89,814	1,819,039
27	L04	IMMUNOSUPPRESSANTS	1,580,619	140,823	1,721,442
28	A06	DRUGS FOR CONSTIPATION	1,431,757	78,096	1,509,853
29	A04	ANTIEMETICS AND ANTINAUSEANTS	937,316	505,612	1,442,928
30	N04	ANTI-PARKINSON DRUGS	1,237,752	168,373	1,406,125
31	J05	ANTIVIRALS FOR SYSTEMIC USE	905,423	469,815	1,375,238
32	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	839,414	421,444	1,260,858
33	S02	OTOLOGICALS	577,554	529,510	1,107,064
34	L02	ENDOCRINE THERAPY	735,861	300,305	1,036,166
35	B03	ANTIANEMIC PREPARATIONS	912,270	117,106	1,029,376
36	A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	866,736	59,208	925,944
37	N07	OTHER NERVOUS SYSTEM DRUGS	678,110	3,130	681,240
38	D10	ANTI-ACNE PREPARATIONS	224,138	151,245	375,383
39	A12	MINERAL SUPPLEMENTS	305,845	53,229	359,074
40	M03	MUSCLE RELAXANTS	267,322	58,878	326,200
41	D05	ANTIPSORIATICS	241,867	62,575	304,442
42	R05	COUGH AND COLD PREPARATIONS	135,181	68,988	204,169
43	G02	OTHER GYNECOLOGICALS	190,969	5,957	196,926
44	A09	DIGESTIVES, INCL. ENZYMES	163,329	637	163,966
45	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	159,765	25	159,790
46	A11	VITAMINS	126,489	32,694	159,183
47	A01	STOMATOLOGICAL PREPARATIONS	98,030	46,637	144,667
48	L03	IMMUNOSTIMULANTS	136,446	43	136,489
49	V03	ALL OTHER THERAPEUTIC PRODUCTS	116,306	11,464	127,770
50	D01	ANTIFUNGALS FOR DERMATOLOGICAL USE	74,015	53,627	127,642

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2017-18 and 2018-19

Section 85 and Section 100A, including Drs Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution***			
	2017-18	2018-19	Prescriptions Change	Percentage Change	2017-18	2018-19	Gov Cost Change	Percentage Change	2017-18	2018-19	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	31,620,539	32,317,335	696,796	2.2%	\$ 1,001,641,253	\$ 955,221,461	-\$ 46,419,792	-4.6%	\$ 236,116,195	\$ 252,815,759	\$ 16,699,564	7.1%
BLOOD AND BLOOD FORMING ORGANS	9,483,030	9,900,560	417,530	4.4%	\$ 646,367,183	\$ 687,579,081	\$ 41,211,898	6.4%	\$ 90,310,381	\$ 100,333,396	\$ 10,023,016	11.1%
CARDIOVASCULAR SYSTEM	64,200,401	64,250,367	49,966	0.1%	\$ 971,050,647	\$ 932,245,155	-\$ 38,805,492	-4.0%	\$ 381,043,811	\$ 375,894,399	-\$ 5,149,411	-1.4%
DERMATOLOGICALS	2,848,407	2,883,777	35,370	1.2%	\$ 65,595,401	\$ 67,770,404	\$ 2,175,003	3.3%	\$ 25,376,375	\$ 27,046,357	\$ 1,669,982	6.6%
GENITO URINARY SYSTEM AND SEX HORMONES	3,787,617	3,974,290	186,673	4.9%	\$ 235,841,436	\$ 239,628,349	\$ 3,786,913	1.6%	\$ 35,655,238	\$ 38,202,420	\$ 2,547,182	7.1%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,602,343	3,563,577	- 38,766	-1.1%	\$ 165,723,944	\$ 169,651,903	\$ 3,927,959	2.4%	\$ 23,402,463	\$ 22,916,368	-\$ 486,095	-2.1%
ANTIINFECTIVES FOR SYSTEMIC USE	12,830,390	12,677,862	- 152,528	-1.2%	\$ 1,900,430,936	\$ 1,228,819,460	-\$ 671,611,476	-35.3%	\$ 81,302,072	\$ 84,902,439	\$ 3,600,367	4.4%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	3,879,096	4,182,151	303,055	7.8%	\$ 3,756,541,905	\$ 4,385,860,422	\$ 629,318,517	16.8%	\$ 56,113,403	\$ 63,215,245	\$ 7,101,842	12.7%
MUSCULO-SKELETAL SYSTEM	7,015,768	6,900,821	- 114,947	-1.6%	\$ 343,319,999	\$ 421,133,368	\$ 77,813,370	22.7%	\$ 42,998,368	\$ 44,017,464	\$ 1,019,096	2.4%
NERVOUS SYSTEM	45,078,060	45,095,412	17,352	0.0%	\$ 1,250,316,530	\$ 1,221,443,517	-\$ 28,873,013	-2.3%	\$ 299,778,041	\$ 295,618,874	-\$ 4,159,166	-1.4%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	79,555	77,328	- 2,227	-2.8%	\$ 2,409,737	\$ 2,547,123	\$ 137,386	5.7%	\$ 655,400	\$ 629,868	-\$ 25,532	-3.9%
RESPIRATORY SYSTEM	12,047,138	11,623,422	- 423,716	-3.5%	\$ 552,318,268	\$ 648,677,179	\$ 96,358,910	17.4%	\$ 136,970,250	\$ 133,357,127	-\$ 3,613,123	-2.6%
SENSORY ORGANS	7,267,075	7,308,929	41,854	0.6%	\$ 627,525,574	\$ 656,038,800	\$ 28,513,226	4.5%	\$ 41,527,354	\$ 41,408,202	-\$ 119,153	-0.3%
VARIOUS	196,096	197,700	1,604	0.8%	\$ 80,470,756	\$ 77,676,414	-\$ 2,794,342	-3.5%	\$ 3,398,421	\$ 3,388,646	-\$ 9,775	-0.3%
UNLESS OTHERWISE CLASSIFIED	140,738	134,948	- 5,790	-4.1%	\$ 4,521,592	\$ 4,425,018	-\$ 96,573	-2.1%	\$ 954,261	\$ 918,353	-\$ 35,908	-3.8%
TOTAL	204,076,253	205,088,479	1,012,226	0.5%	\$ 11,604,075,163	\$ 11,698,717,656	\$ 94,642,493	0.8%	\$ 1,455,602,031	\$ 1,484,664,919	\$ 29,062,888	2.0%

ATC Group Level 1	Total Cost*				Average Price**			
	2017-18	2018-19	Total Cost Change	Percentage Change	2017-18	2018-19	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$ 1,237,757,448	\$ 1,208,037,220	-\$ 29,720,228	-2.4%	\$ 39.14	\$ 37.38	-\$ 1.76	-4.5%
BLOOD AND BLOOD FORMING ORGANS	\$ 736,677,564	\$ 787,912,478	\$ 51,234,914	7.0%	\$ 77.68	\$ 79.58	\$ 1.90	2.4%
CARDIOVASCULAR SYSTEM	\$ 1,352,094,458	\$ 1,308,139,554	-\$ 43,954,904	-3.3%	\$ 21.06	\$ 20.36	-\$ 0.70	-3.3%
DERMATOLOGICALS	\$ 90,971,776	\$ 94,816,761	\$ 3,844,985	4.2%	\$ 31.94	\$ 32.88	\$ 0.94	2.9%
GENITO URINARY SYSTEM AND SEX HORMONES	\$ 271,496,674	\$ 277,830,769	\$ 6,334,095	2.3%	\$ 71.68	\$ 69.91	-\$ 1.77	-2.5%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$ 189,126,407	\$ 192,568,271	\$ 3,441,864	1.8%	\$ 52.50	\$ 54.04	\$ 1.54	2.9%
ANTIINFECTIVES FOR SYSTEMIC USE	\$ 1,981,733,008	\$ 1,313,721,899	-\$ 668,011,109	-33.7%	\$ 154.46	\$ 103.62	-\$ 50.84	-32.9%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$ 3,812,655,308	\$ 4,449,075,668	\$ 636,420,359	16.7%	\$ 982.87	\$ 1,063.82	\$ 80.95	8.2%
MUSCULO-SKELETAL SYSTEM	\$ 386,318,366	\$ 465,150,832	\$ 78,832,466	20.4%	\$ 55.06	\$ 67.41	\$ 12.35	22.4%
NERVOUS SYSTEM	\$ 1,550,094,571	\$ 1,517,062,392	-\$ 33,032,179	-2.1%	\$ 34.39	\$ 33.64	-\$ 0.75	-2.2%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$ 3,065,137	\$ 3,176,991	\$ 111,854	3.6%	\$ 38.53	\$ 41.08	\$ 2.55	6.6%
RESPIRATORY SYSTEM	\$ 689,288,518	\$ 782,034,306	\$ 92,745,787	13.5%	\$ 57.22	\$ 67.28	\$ 10.06	17.6%
SENSORY ORGANS	\$ 669,052,928	\$ 697,447,002	\$ 28,394,074	4.2%	\$ 92.07	\$ 95.42	\$ 3.35	3.6%
VARIOUS	\$ 83,869,177	\$ 81,065,060	-\$ 2,804,117	-3.3%	\$ 427.69	\$ 410.04	-\$ 17.65	-4.1%
UNLESS OTHERWISE CLASSIFIED	\$ 5,475,853	\$ 5,343,372	-\$ 132,481	-2.4%	\$ 38.91	\$ 39.60	\$ 0.69	1.8%
TOTAL	\$ 13,059,677,194	\$ 13,183,382,575	\$ 123,705,381	0.9%	\$ 63.99	\$ 64.28	\$ 0.29	0.4%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

^ Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 9(a): Top 35 Drugs Sorted by Highest Change to Government Cost, 2017-18 and 2018-19
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2017-18					2018-19					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	OCRELIZUMAB	1,568	\$ 25,808,736	\$ 48,954	\$ 25,857,690	\$ 16,491	6,202	\$ 105,039,805	\$ 195,312	\$ 105,235,117	\$ 16,968	\$ 79,231,069	306.99%
2	IBRUTINIB	5,585	\$ 50,132,693	\$ 84,701	\$ 50,217,394	\$ 8,991	13,556	\$ 125,939,876	\$ 199,570	\$ 126,139,446	\$ 9,305	\$ 75,807,183	151.21%
3	PEMBROLIZUMAB	16,916	\$ 142,880,020	\$ 73,499	\$ 142,953,519	\$ 8,451	24,810	\$ 212,942,681	\$ 116,610	\$ 213,059,291	\$ 8,588	\$ 70,062,661	49.04%
4	NUSINERSEN	49	\$ 8,469,223	\$ 777	\$ 8,470,000	\$ 172,857	583	\$ 67,639,822	\$ 10,178	\$ 67,650,000	\$ 116,038	\$ 59,170,599	698.65%
5	USTEKINUMAB	18,445	\$ 118,456,961	\$ 542,722	\$ 118,999,683	\$ 6,452	25,556	\$ 177,539,808	\$ 759,620	\$ 178,299,428	\$ 6,977	\$ 59,082,847	49.88%
6	NIVOLUMAB	41,838	\$ 208,063,445	\$ 152,113	\$ 208,215,558	\$ 4,977	52,215	\$ 258,796,640	\$ 207,176	\$ 259,003,816	\$ 4,960	\$ 50,733,195	24.38%
7	APIXABAN	1,544,939	\$ 125,504,947	\$ 17,455,494	\$ 142,960,441	\$ 93	2,000,103	\$ 162,331,236	\$ 23,258,998	\$ 185,590,234	\$ 93	\$ 36,826,289	29.34%
8	AFLIBERCEPT	239,294	\$ 304,222,941	\$ 3,429,268	\$ 307,652,209	\$ 1,286	273,387	\$ 338,561,125	\$ 4,084,496	\$ 342,645,621	\$ 1,253	\$ 34,338,184	11.29%
9	CARFILZOMIB	8,272	\$ 20,727,033	\$ 13,623	\$ 20,740,655	\$ 2,507	22,518	\$ 52,434,776	\$ 30,976	\$ 52,465,752	\$ 2,330	\$ 31,707,743	152.98%
10	DENOSUMAB	648,226	\$ 182,112,015	\$ 7,487,803	\$ 189,599,818	\$ 292	759,525	\$ 211,437,708	\$ 8,968,119	\$ 220,405,827	\$ 290	\$ 29,325,693	16.10%
11	ATEZOLIZUMAB	302	\$ 2,306,704	\$ 2,470	\$ 2,309,174	\$ 7,646	3,941	\$ 30,045,314	\$ 24,207	\$ 30,069,521	\$ 7,630	\$ 27,338,609	1,202.52%
12	CLADRIBINE	494	\$ 525,032	\$ 3,299	\$ 528,331	\$ 1,070	1,832	\$ 25,700,342	\$ 38,769	\$ 25,739,111	\$ 14,050	\$ 25,175,311	4,795.01%
13	PEGFILGRASTIM	35,170	\$ 43,843,497	\$ 956,492	\$ 44,799,989	\$ 1,274	58,122	\$ 68,830,618	\$ 1,598,175	\$ 70,428,793	\$ 1,212	\$ 24,987,120	56.99%
14	LENALIDOMIDE	20,148	\$ 123,618,271	\$ 291,758	\$ 123,910,029	\$ 6,150	23,780	\$ 144,816,000	\$ 369,680	\$ 145,185,680	\$ 6,105	\$ 21,197,729	17.15%
15	SACUBITRIL + VALSARTAN	114,897	\$ 21,568,876	\$ 1,496,165	\$ 23,065,041	\$ 201	228,858	\$ 42,351,896	\$ 3,011,543	\$ 45,363,439	\$ 198	\$ 20,783,020	96.36%
16	TENOFOVIR + EMTRICITABINE	23,511	\$ 10,823,150	\$ 757,862	\$ 11,581,012	\$ 493	163,912	\$ 31,519,122	\$ 5,873,685	\$ 37,392,807	\$ 228	\$ 20,695,972	191.22%
17	IPILIMUMAB	2,082	\$ 64,374,791	\$ 22,823	\$ 64,397,614	\$ 30,931	2,854	\$ 81,646,006	\$ 33,748	\$ 81,679,754	\$ 28,619	\$ 17,271,215	26.83%
18	DULAGLUTIDE	1,388	\$ 153,494	\$ 27,666	\$ 181,159	\$ 131	153,855	\$ 17,240,620	\$ 2,843,458	\$ 20,084,078	\$ 131	\$ 17,087,127	11,132.14%
19	FLUTICASON FUROATE + UMECLIDINIUM + VILANTEROL	3,234	\$ 284,879	\$ 29,408	\$ 314,287	\$ 97	195,814	\$ 17,207,080	\$ 1,861,355	\$ 19,068,435	\$ 97	\$ 16,922,202	5,940.14%
20	CABOZANTINIB	68	\$ 706,353	\$ 1,297	\$ 707,650	\$ 10,407	1,483	\$ 15,292,822	\$ 27,299	\$ 15,320,121	\$ 10,330	\$ 14,586,469	2,065.04%
21	TOFACITINIB	38,591	\$ 48,151,121	\$ 750,489	\$ 48,901,610	\$ 1,267	50,119	\$ 62,519,401	\$ 1,003,489	\$ 63,522,889	\$ 1,267	\$ 14,368,280	29.84%
22	RIVAROXABAN	1,701,732	\$ 125,758,174	\$ 22,891,731	\$ 148,649,905	\$ 87	1,898,852	\$ 140,061,915	\$ 26,232,215	\$ 166,294,130	\$ 88	\$ 14,303,741	11.37%
23	SECUKINUMAB	35,877	\$ 56,898,052	\$ 983,686	\$ 57,881,738	\$ 1,613	45,221	\$ 69,625,480	\$ 1,248,955	\$ 70,874,435	\$ 1,567	\$ 12,727,428	22.37%
24	VEDOLIZUMAB	12,180	\$ 37,744,882	\$ 380,269	\$ 38,125,151	\$ 3,130	16,268	\$ 50,389,492	\$ 518,535	\$ 50,908,027	\$ 3,129	\$ 12,644,610	33.50%
25	ENZALUTAMIDE	23,333	\$ 86,726,608	\$ 257,554	\$ 86,984,163	\$ 3,728	26,728	\$ 99,368,482	\$ 308,760	\$ 99,677,242	\$ 3,729	\$ 12,641,874	14.58%
26	FERRIC CARBOXYMALTOSE	248,275	\$ 68,180,398	\$ 5,963,897	\$ 74,144,295	\$ 299	289,042	\$ 79,397,460	\$ 7,121,112	\$ 86,518,572	\$ 299	\$ 11,217,062	16.45%
27	OBINUTUZUMAB	1,672	\$ 9,110,852	\$ 3,499	\$ 9,114,351	\$ 5,451	3,682	\$ 20,071,087	\$ 13,781	\$ 20,084,868	\$ 5,455	\$ 10,960,235	120.30%
28	OMALIZUMAB	17,604	\$ 17,740,743	\$ 409,354	\$ 18,150,098	\$ 1,031	29,618	\$ 28,301,272	\$ 746,316	\$ 29,047,589	\$ 981	\$ 10,560,529	59.53%
29	ALECTINIB	692	\$ 4,825,063	\$ 19,020	\$ 4,844,083	\$ 7,000	2,168	\$ 15,086,900	\$ 54,837	\$ 15,141,736	\$ 6,984	\$ 10,261,836	212.68%
30	NINTEDANIB	5,125	\$ 15,184,558	\$ 66,472	\$ 15,251,030	\$ 2,976	8,357	\$ 24,552,527	\$ 104,498	\$ 24,657,025	\$ 2,950	\$ 9,367,969	61.69%
31	IXEKIZUMAB	4,215	\$ 14,224,748	\$ 129,374	\$ 14,354,122	\$ 3,405	6,690	\$ 22,604,745	\$ 207,472	\$ 22,812,218	\$ 3,410	\$ 8,379,997	58.91%
32	EMPAGLIFLOZIN	487,996	\$ 22,107,420	\$ 7,948,928	\$ 30,056,348	\$ 62	667,057	\$ 30,316,226	\$ 10,928,743	\$ 41,244,968	\$ 62	\$ 8,208,806	37.13%
33	LEVODOPA + CARBIDOPA	275,598	\$ 51,015,487	\$ 1,887,618	\$ 52,903,105	\$ 192	272,601	\$ 59,041,741	\$ 1,813,094	\$ 60,854,835	\$ 223	\$ 8,026,254	15.73%
34	MEPOLIZUMAB	6,814	\$ 11,231,931	\$ 160,671	\$ 11,392,603	\$ 1,672	11,456	\$ 18,905,404	\$ 264,326	\$ 19,169,730	\$ 1,673	\$ 7,673,473	68.32%
35	EMPAGLIFLOZIN + METFORMIN	349,034	\$ 15,912,562	\$ 6,560,249	\$ 22,472,810	\$ 64	516,148	\$ 23,468,732	\$ 9,882,598	\$ 33,351,330	\$ 65	\$ 7,556,171	47.49%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 9(b): Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2017-18 and 2018-19
 Section 85 and Section 100A, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2017-18					2018-19					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	APIXABAN	1,544,939	\$ 125,504,947	\$ 17,455,494	\$ 142,960,441	\$ 92.53	2,000,103	\$ 162,331,236	\$ 23,258,998	\$ 185,590,234	\$ 92.79	455,164	29.46%
2	ROSUVASTATIN	6,931,314	\$ 83,482,322	\$ 36,475,647	\$ 119,957,969	\$ 17.31	7,292,825	\$ 89,291,516	\$ 38,881,763	\$ 128,173,279	\$ 17.58	361,511	5.22%
3	RIVAROXABAN	1,701,732	\$ 125,758,174	\$ 22,891,731	\$ 148,649,905	\$ 87.35	1,898,852	\$ 140,061,915	\$ 26,232,215	\$ 166,294,130	\$ 87.58	197,120	11.58%
4	FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL	3,234	\$ 284,879	\$ 29,408	\$ 314,287	\$ 97.18	195,814	\$ 17,207,080	\$ 1,861,355	\$ 19,068,435	\$ 97.38	192,580	5,954.85%
5	EMPAGLIFLOZIN	487,996	\$ 22,107,420	\$ 7,948,928	\$ 30,056,348	\$ 61.59	667,057	\$ 30,316,226	\$ 10,928,743	\$ 41,244,968	\$ 61.83	179,061	36.69%
6	EMPAGLIFLOZIN + METFORMIN	349,034	\$ 15,912,562	\$ 6,560,249	\$ 22,472,810	\$ 64.39	516,148	\$ 23,468,732	\$ 9,882,598	\$ 33,351,330	\$ 64.62	167,114	47.88%
7	PANTOPRAZOLE	4,841,333	\$ 44,842,314	\$ 24,051,819	\$ 68,894,133	\$ 14.23	4,999,967	\$ 46,314,333	\$ 25,099,114	\$ 71,413,446	\$ 14.28	158,634	3.28%
8	DUTASTERIDE + TAMSULOSIN	906,352	\$ 25,519,719	\$ 4,527,107	\$ 30,046,826	\$ 33.15	1,062,251	\$ 28,747,590	\$ 5,361,107	\$ 34,108,697	\$ 32.11	155,899	17.20%
9	DULAGLUTIDE	1,388	\$ 153,494	\$ 27,666	\$ 181,159	\$ 130.52	153,855	\$ 17,240,620	\$ 2,843,458	\$ 20,084,078	\$ 130.54	152,467	10,984.65%
10	TENOFOVIR + EMTRICITABINE	23,511	\$ 10,823,150	\$ 757,862	\$ 11,581,012	\$ 492.58	163,912	\$ 31,519,122	\$ 5,873,685	\$ 37,392,807	\$ 228.13	140,401	597.17%
11	AMLODIPINE	2,378,292	\$ 16,978,160	\$ 12,120,483	\$ 29,098,643	\$ 12.24	2,510,219	\$ 18,322,082	\$ 12,976,489	\$ 31,298,571	\$ 12.47	131,927	5.55%
12	EZETIMIBE + ATORVASTATIN	408,721	\$ 21,008,311	\$ 6,858,452	\$ 27,866,763	\$ 68.18	537,456	\$ 15,408,397	\$ 9,424,411	\$ 24,832,808	\$ 46.20	128,735	31.50%
13	TAPENTADOL	579,820	\$ 19,849,723	\$ 4,984,843	\$ 24,834,566	\$ 42.83	701,708	\$ 23,875,154	\$ 5,961,732	\$ 29,836,886	\$ 42.52	121,888	21.02%
14	SACUBITRIL + VALSARTAN	114,897	\$ 21,568,876	\$ 1,496,165	\$ 23,065,041	\$ 200.75	228,858	\$ 42,351,896	\$ 3,011,543	\$ 45,363,439	\$ 198.22	113,961	99.19%
15	BISOPROLOL	1,055,334	\$ 15,860,964	\$ 5,113,864	\$ 20,974,829	\$ 19.88	1,167,622	\$ 17,373,713	\$ 5,731,585	\$ 23,105,298	\$ 19.79	112,288	10.64%
16	SITAGLIPTIN + METFORMIN	1,283,143	\$ 54,592,357	\$ 21,220,132	\$ 75,812,489	\$ 59.08	1,394,794	\$ 57,607,511	\$ 23,507,469	\$ 81,114,980	\$ 58.16	111,651	8.70%
17	DENOSUMAB	648,226	\$ 182,112,015	\$ 7,487,803	\$ 189,599,818	\$ 292.49	759,525	\$ 211,437,708	\$ 8,968,119	\$ 220,405,827	\$ 290.19	111,299	17.17%
18	LINAGLIPTIN	346,354	\$ 17,130,212	\$ 3,486,835	\$ 20,617,047	\$ 59.53	455,053	\$ 22,477,674	\$ 4,707,821	\$ 27,185,495	\$ 59.74	108,699	31.38%
19	ESCITALOPRAM	1,837,106	\$ 15,233,893	\$ 9,961,595	\$ 25,195,488	\$ 13.71	1,935,627	\$ 16,389,464	\$ 10,609,513	\$ 26,998,978	\$ 13.95	98,521	5.36%
20	MIRTAZAPINE	1,794,127	\$ 18,967,219	\$ 8,858,623	\$ 27,825,842	\$ 15.51	1,891,830	\$ 20,082,793	\$ 9,430,727	\$ 29,513,521	\$ 15.60	97,703	5.45%
21	EMPAGLIFLOZIN + LINAGLIPTIN	5,215	\$ 340,127	\$ 99,184	\$ 439,311	\$ 84.24	87,784	\$ 5,709,266	\$ 1,705,807	\$ 7,415,072	\$ 84.47	82,569	1,583.30%
22	HYALURONATE SODIUM	133,820	\$ 4,051,607	\$ 639,939	\$ 4,691,546	\$ 35.06	211,797	\$ 6,236,139	\$ 1,032,305	\$ 7,268,445	\$ 34.32	77,977	58.27%
23	FLUTICASONE FUROATE + VILANTEROL	529,060	\$ 25,663,163	\$ 8,742,480	\$ 34,405,644	\$ 65.03	605,460	\$ 28,909,840	\$ 10,669,254	\$ 39,579,093	\$ 65.37	76,400	14.44%
24	PARACETAMOL + CODEINE	2,246,946	\$ 27,133,379	\$ 11,327,927	\$ 38,461,306	\$ 17.12	2,317,263	\$ 27,866,933	\$ 11,788,034	\$ 39,654,967	\$ 17.11	70,317	3.13%
25	SERTRALINE	1,958,520	\$ 15,781,234	\$ 10,431,988	\$ 26,213,221	\$ 13.38	2,026,922	\$ 16,696,693	\$ 10,929,070	\$ 27,625,763	\$ 13.63	68,402	3.49%
26	AMITRIPTYLINE	1,489,184	\$ 13,945,068	\$ 7,146,421	\$ 21,091,489	\$ 14.16	1,556,818	\$ 14,808,112	\$ 7,577,989	\$ 22,386,101	\$ 14.38	67,634	4.54%
27	TIOTROPIUM + OLODATEROL	168,151	\$ 13,452,211	\$ 1,572,350	\$ 15,024,561	\$ 89.35	231,419	\$ 17,046,563	\$ 2,218,521	\$ 19,265,084	\$ 83.25	63,268	37.63%
28	RISEDRONATE	451,169	\$ 14,122,419	\$ 2,362,577	\$ 16,484,996	\$ 36.54	512,764	\$ 16,032,717	\$ 2,688,969	\$ 18,721,686	\$ 36.51	61,595	13.65%
29	LISDEXAMFETAMINE	210,902	\$ 20,499,334	\$ 4,225,861	\$ 24,725,195	\$ 117.24	272,386	\$ 26,269,430	\$ 5,745,499	\$ 32,014,928	\$ 117.54	61,484	29.15%
30	RANITIDINE	749,448	\$ 7,462,148	\$ 3,551,017	\$ 11,013,165	\$ 14.70	810,752	\$ 8,216,074	\$ 3,881,617	\$ 12,097,691	\$ 14.92	61,304	8.18%
31	PERINDOPRIL + AMLODIPINE	1,314,053	\$ 14,169,551	\$ 7,241,656	\$ 21,411,207	\$ 16.29	1,370,167	\$ 14,759,108	\$ 7,649,762	\$ 22,408,870	\$ 16.35	56,114	4.27%
32	TELMISARTAN	2,087,160	\$ 20,147,965	\$ 11,232,715	\$ 31,380,680	\$ 15.04	2,141,254	\$ 19,467,833	\$ 11,687,766	\$ 31,155,599	\$ 14.55	54,094	2.59%
33	LINAGLIPTIN + METFORMIN	208,901	\$ 9,845,406	\$ 3,159,617	\$ 13,005,023	\$ 62.25	260,480	\$ 12,329,700	\$ 3,946,463	\$ 16,276,163	\$ 62.49	51,579	24.69%
34	DULOXETINE	967,873	\$ 12,995,964	\$ 4,983,215	\$ 17,979,179	\$ 18.58	1,019,192	\$ 13,549,676	\$ 5,225,103	\$ 18,774,779	\$ 18.42	51,319	5.30%
35	DAPAGLIFLOZIN + METFORMIN	243,782	\$ 10,025,658	\$ 4,790,582	\$ 14,816,240	\$ 60.78	292,073	\$ 11,861,609	\$ 5,783,416	\$ 17,645,025	\$ 60.41	48,291	19.81%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

^ Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 10(a): PBS Section 85 Prescription Volume, 2015-16 to 2018-19

Section 85 only, including Drs Bag and under co-payment prescriptions

Prescription Type	2015-16	2016-17	2017-18	2018-19
Over Co-payment	204,073,583	199,784,150	201,430,521	202,275,451
Under Co-payment	81,430,538	86,196,502	89,435,371	93,863,877
Total	285,504,121	285,980,652	290,865,892	296,139,328





Table 10(b): PBS Section 85 expenditure, 2015-16 to 2018-19

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Expenditure Type	2015-16	2016-17	2017-18	2018-19
Government Cost	\$ 8,055,467,620	\$ 8,890,219,373	\$ 8,463,949,540	\$ 8,211,647,712
Patient Contribution*	\$ 1,363,172,788	\$ 1,366,210,056	\$ 1,415,421,728	\$ 1,440,022,615
Total Cost**	\$ 9,418,640,408	\$ 10,256,429,429	\$ 9,879,371,268	\$ 9,651,670,327



* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

Table 11: PBS Prescriptions and Government Cost by Formulary, 2018-19

Section 85 and Section 100[^], including under co-payment prescriptions and Drs Bag

Formulary Group ¹	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Percentage	Government Cost	Percentage
F1	26,453,909	3,271,655	29,725,564	9.9%	\$ 6,913,192,396	59.1%
F2	168,676,152	89,259,151	257,935,303	86.3%	\$ 3,619,536,047	30.9%
Combination Drugs ²	9,816,038	1,357,810	11,173,848	3.7%	\$ 1,161,394,725	9.9%
Other ³	142,380	37,861	180,241	0.1%	\$ 4,594,489	0.0%
Total	205,088,479	93,926,477	299,014,956	100.0%	\$ 11,698,717,656	100.0%

Notes:

1. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2. Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands. Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply. Allocation to F1 or F2 is determined by legislative instrument.
2. Combination Drugs are not allocated to any formulary.
3. The category 'Other' includes extemporaneously prepared items.
- [^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 12(a): Top 20 Responsible Persons by Total Cost, 2018-19

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,362,264	1,382,839	5,745,103	\$ 980,198,924	\$ 41,707,883	\$ 1,021,906,807	\$ 884,199,313
2	JANSSEN-CILAG PTY LTD	1,951,675	393,246	2,344,921	\$ 695,791,578	\$ 20,966,158	\$ 716,757,735	\$ 613,754,438
3	ALPHAPHARM PTY LTD	33,408,045	17,177,925	50,585,970	\$ 493,376,417	\$ 183,460,854	\$ 676,837,271	\$ 338,222,835
4	GILEAD SCIENCES PTY LIMITED	192,660	n.p.	192,660	\$ 617,437,032	\$ 5,734,011	\$ 623,171,042	\$ 608,666,815
5	APOTEX PTY LTD	34,012,426	14,924,702	48,937,128	\$ 434,319,267	\$ 182,069,045	\$ 616,388,312	\$ 257,303,097
6	BAYER AUSTRALIA LTD	3,264,193	1,435,816	4,700,009	\$ 553,602,853	\$ 43,179,741	\$ 596,782,594	\$ 517,758,828
7	ABBVIE PTY LTD	295,407	52	295,459	\$ 570,094,704	\$ 7,512,354	\$ 577,607,057	\$ 537,212,135
8	PFIZER AUSTRALIA PTY LTD	11,007,407	5,194,795	16,202,202	\$ 443,071,145	\$ 85,918,527	\$ 528,989,672	\$ 404,004,676
9	ASTRAZENECA PTY LTD	10,351,476	3,529,514	13,880,990	\$ 353,972,691	\$ 100,469,034	\$ 454,441,725	\$ 329,676,936
10	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	6,465,581	1,233,846	7,699,427	\$ 338,000,955	\$ 85,663,389	\$ 423,664,344	\$ 339,581,542
11	BOEHRINGER INGELHEIM PTY LTD	7,148,627	1,652,452	8,801,079	\$ 285,524,670	\$ 69,263,369	\$ 354,788,039	\$ 264,230,677
12	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,503,967	3,570,768	12,074,735	\$ 286,308,951	\$ 54,260,278	\$ 340,569,228	\$ 237,387,357
13	ROCHE PRODUCTS PTY LTD	838,402	203,550	1,041,952	\$ 319,468,686	\$ 8,496,313	\$ 327,964,999	\$ 267,313,062
14	AMGEN AUSTRALIA PTY LIMITED	850,462	10	850,472	\$ 310,693,590	\$ 10,523,004	\$ 321,216,594	\$ 269,043,088
15	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,741,913	844,764	6,586,677	\$ 235,685,168	\$ 68,363,793	\$ 304,048,961	\$ 210,988,563
16	SANDOZ PTY LTD	14,279,463	16,626,166	30,905,629	\$ 215,337,090	\$ 82,109,326	\$ 297,446,416	\$ 183,929,855
17	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	2,133,875	578	2,134,453	\$ 265,795,505	\$ 25,992,710	\$ 291,788,215	\$ 245,522,535
18	ARROW PHARMA PTY LTD	14,960,526	6,347,655	21,308,181	\$ 180,919,225	\$ 80,579,357	\$ 261,498,582	\$ 111,617,389
19	MUNDIPHARMA PTY LIMITED	4,422,150	635,583	5,057,733	\$ 188,256,267	\$ 34,582,155	\$ 222,838,422	\$ 154,006,323
20	CELGENE PTY LIMITED	33,124	-	33,124	\$ 180,509,888	\$ 538,787	\$ 181,048,675	\$ 121,560,521

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

n.p. - Not Published. Cells with fewer than 6 prescriptions have been suppressed and excluded from totals.

Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2018-19

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	APOTEX PTY LTD	34,012,426	14,924,702	48,937,128	\$ 434,319,267	\$ 182,069,045	\$ 616,388,312	\$ 257,303,097
2	ALPHAPHARM PTY LTD	33,408,045	17,177,925	50,585,970	\$ 493,376,417	\$ 183,460,854	\$ 676,837,271	\$ 338,222,835
3	ARROW PHARMA PTY LTD	14,960,526	6,347,655	21,308,181	\$ 180,919,225	\$ 80,579,357	\$ 261,498,582	\$ 111,617,389
4	SANDOZ PTY LTD	14,279,463	16,626,166	30,905,629	\$ 215,337,090	\$ 82,109,326	\$ 297,446,416	\$ 183,929,855
5	PFIZER AUSTRALIA PTY LTD	11,007,407	5,194,795	16,202,202	\$ 443,071,145	\$ 85,918,527	\$ 528,989,672	\$ 404,004,676
6	ASTRAZENECA PTY LTD	10,351,476	3,529,514	13,880,990	\$ 353,972,691	\$ 100,469,034	\$ 454,441,725	\$ 329,676,936
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,503,967	3,570,768	12,074,735	\$ 286,308,951	\$ 54,260,278	\$ 340,569,228	\$ 237,387,357
8	BOEHRINGER INGELHEIM PTY LTD	7,148,627	1,652,452	8,801,079	\$ 285,524,670	\$ 69,263,369	\$ 354,788,039	\$ 264,230,677
9	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	6,465,581	1,233,846	7,699,427	\$ 338,000,955	\$ 85,663,389	\$ 423,664,344	\$ 339,581,542
10	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,741,913	844,764	6,586,677	\$ 235,685,168	\$ 68,363,793	\$ 304,048,961	\$ 210,988,563
11	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	4,567,731	4,182,636	8,750,367	\$ 69,926,652	\$ 25,601,935	\$ 95,528,587	\$ 60,550,614
12	MUNDIPHARMA PTY LIMITED	4,422,150	635,583	5,057,733	\$ 188,256,267	\$ 34,582,155	\$ 222,838,422	\$ 154,006,323
13	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,362,264	1,382,839	5,745,103	\$ 980,198,924	\$ 41,707,883	\$ 1,021,906,807	\$ 884,199,313
14	ASPEN PHARMA PTY LTD	4,324,634	2,314,352	6,638,986	\$ 68,444,904	\$ 24,921,068	\$ 93,365,973	\$ 40,616,536
15	BAYER AUSTRALIA LTD	3,264,193	1,435,816	4,700,009	\$ 553,602,853	\$ 43,179,741	\$ 596,782,594	\$ 517,758,828
16	MYLAN HEALTH PTY LTD	3,059,447	1,442,583	4,502,030	\$ 80,137,529	\$ 16,976,437	\$ 97,113,967	\$ 75,806,459
17	FAWNS AND MCALLAN PROPRIETARY LIMITED	2,929,115	1,918,504	4,847,619	\$ 40,658,825	\$ 14,518,401	\$ 55,177,226	\$ 33,394,966
18	SERVIER LABORATORIES (AUST.) PTY LTD	2,407,069	1,445,577	3,852,646	\$ 45,141,998	\$ 13,604,715	\$ 58,746,712	\$ 35,875,338
19	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	2,133,875	578	2,134,453	\$ 265,795,505	\$ 25,992,710	\$ 291,788,215	\$ 245,522,535
20	JANSSEN-CILAG PTY LTD	1,951,675	393,246	2,344,921	\$ 695,791,578	\$ 20,966,158	\$ 716,757,735	\$ 613,754,438

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2018-19

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	ALPHAPHARM PTY LTD	33,408,045	17,177,925	50,585,970	\$ 493,376,417	\$ 183,460,854	\$ 676,837,271	\$ 338,222,835
2	APOTEX PTY LTD	34,012,426	14,924,702	48,937,128	\$ 434,319,267	\$ 182,069,045	\$ 616,388,312	\$ 257,303,097
3	SANDOZ PTY LTD	14,279,463	16,626,166	30,905,629	\$ 215,337,090	\$ 82,109,326	\$ 297,446,416	\$ 183,929,855
4	ARROW PHARMA PTY LTD	14,960,526	6,347,655	21,308,181	\$ 180,919,225	\$ 80,579,357	\$ 261,498,582	\$ 111,617,389
5	PFIZER AUSTRALIA PTY LTD	11,007,407	5,194,795	16,202,202	\$ 443,071,145	\$ 85,918,527	\$ 528,989,672	\$ 404,004,676
6	ASTRAZENECA PTY LTD	10,351,476	3,529,514	13,880,990	\$ 353,972,691	\$ 100,469,034	\$ 454,441,725	\$ 329,676,936
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,503,967	3,570,768	12,074,735	\$ 286,308,951	\$ 54,260,278	\$ 340,569,228	\$ 237,387,357
8	BOEHRINGER INGELHEIM PTY LTD	7,148,627	1,652,452	8,801,079	\$ 285,524,670	\$ 69,263,369	\$ 354,788,039	\$ 264,230,677
9	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	4,567,731	4,182,636	8,750,367	\$ 69,926,652	\$ 25,601,935	\$ 95,528,587	\$ 60,550,614
10	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	6,465,581	1,233,846	7,699,427	\$ 338,000,955	\$ 85,663,389	\$ 423,664,344	\$ 339,581,542
11	ASPEN PHARMA PTY LTD	4,324,634	2,314,352	6,638,986	\$ 68,444,904	\$ 24,921,068	\$ 93,365,973	\$ 40,616,536
12	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,741,913	844,764	6,586,677	\$ 235,685,168	\$ 68,363,793	\$ 304,048,961	\$ 210,988,563
13	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	4,362,264	1,382,839	5,745,103	\$ 980,198,924	\$ 41,707,883	\$ 1,021,906,807	\$ 884,199,313
14	MUNDIPHARMA PTY LIMITED	4,422,150	635,583	5,057,733	\$ 188,256,267	\$ 34,582,155	\$ 222,838,422	\$ 154,006,323
15	FAWNS AND MCALLAN PROPRIETARY LIMITED	2,929,115	1,918,504	4,847,619	\$ 40,658,825	\$ 14,518,401	\$ 55,177,226	\$ 33,394,966
16	BAYER AUSTRALIA LTD	3,264,193	1,435,816	4,700,009	\$ 553,602,853	\$ 43,179,741	\$ 596,782,594	\$ 517,758,828
17	MYLAN HEALTH PTY LTD	3,059,447	1,442,583	4,502,030	\$ 80,137,529	\$ 16,976,437	\$ 97,113,967	\$ 75,806,459
18	SERVIER LABORATORIES (AUST.) PTY LTD	2,407,069	1,445,577	3,852,646	\$ 45,141,998	\$ 13,604,715	\$ 58,746,712	\$ 35,875,338
19	JANSSEN-CILAG PTY LTD	1,951,675	393,246	2,344,921	\$ 695,791,578	\$ 20,966,158	\$ 716,757,735	\$ 613,754,438
20	TAKEDA PHARMACEUTICALS AUSTRALIA PTY LTD	1,640,914	559,833	2,200,747	\$ 69,858,108	\$ 9,875,364	\$ 79,733,472	\$ 45,650,089

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 13: Number of PBS Approved Suppliers, 30 June 2019

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,886	40	-	2
VIC	1,369	35	69	1
QLD	1,151	36	51	-
SA	459	10	15	1
WA	626	5	19	3
TAS	153	4	4	2
NT	40	1	6	-
ACT	78	5	-	-
Total	5,762	136	164	9

Table 14: PBS Brand Premiums, 2018-19

Section 85 and Section 100[^], excluding Drs Bag and including under co-payment prescriptions

	2018-19
Number of brands listed on the PBS(a)	5,282
Number of brands with a premium(a)	374
% of brands with a premium	7.1%
Average brand premium	\$4.66
Weighted average brand premium(b)	\$4.04
Brand premium range	\$0.25 to \$35.30
Prescriptions (millions) dispensed with a brand premium	36.5
Prescriptions (millions) dispensed at the benchmark level (c)	127.4
% of prescriptions dispensed at benchmark level	77.7%

Notes:

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2019 PBS Schedule.

(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium

(c) Includes only items where at least one brand is listed with a premium.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 15(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2018-19

Section 85 and Section 100*, excluding Drs Bag and under co-payment prescriptions

Prescription Type	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	50,628,280	27%	4,693,390	29%	1,370,038	16%	56,691,708	27%
Non-Discounted	134,236,390	73%	11,693,913	71%	6,945,577	84%	152,875,880	73%
Grand Total	184,864,670	100%	16,387,303	100%	8,315,615	100%	209,567,588	100%

Table 15(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2018-19

Section 85 and Section 100*, excluding Drs Bag and under co-payment prescriptions

Discount Range	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	48,941,567	96.7%	4,586,287	97.7%	1,309,823	95.6%	54,837,677	96.7%
0.50 - LT \$1.00	715,774	1.4%	60,291	1.3%	24,314	1.8%	800,379	1.4%
LT 50c	631,493	1.2%	24,155	0.5%	24,126	1.8%	679,774	1.2%
Other	339,446	0.7%	22,657	0.5%	11,775	0.9%	373,878	0.7%
Grand Total	50,628,280	100.0%	4,693,390	100.0%	1,370,038	100.0%	56,691,708	100.0%

* Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 16(a): PBS/RPBS Continued Dispensing Medicines Prescriptions by Dispensing Pharmacy State, 2018-19

Section 85 and Section 100^, including Drs Bag and under co-payment prescriptions

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	1,551	1,126	372	246	334	350	13	351	4,343
FLUVASTATIN	3	-	-	-	-	-	-	1	4
LEVONORGESTREL	35	29	9	17	8	23	-	15	136
LEVONORGESTREL + ETHINYLESTRADIOL	887	889	447	268	189	424	3	182	3,289
NORETHISTERONE	11	8	4	1	6	1	-	4	35
NORETHISTERONE + ETHINYLESTRADIOL	88	52	28	13	9	40	-	18	248
NORETHISTERONE + MESTRANOL	4	2	1	-	1	1	-	-	9
PRAVASTATIN	86	63	10	12	21	11	-	21	224
ROSUVASTATIN	1,855	1,413	446	304	330	503	3	278	5,132
SIMVASTATIN	312	280	43	45	64	88	-	80	912
Grand Total	4,832	3,862	1,360	906	962	1,441	19	950	14,332

Table 16(b): PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State, 2018-19

Section 85 and Section 100^, including Drs Bag and under co-payment prescriptions

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	\$ 9,325	\$ 6,655	\$ 2,112	\$ 1,223	\$ 1,933	\$ 2,137	\$ 50	\$ 1,757	\$ 25,190
FLUVASTATIN	\$ 85	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 39	\$ 124
LEVONORGESTREL	\$ 63	\$ 88	\$ -	\$ 38	\$ 25	\$ 75	\$ -	\$ 25	\$ 314
LEVONORGESTREL + ETHINYLESTRADIOL	\$ 2,028	\$ 1,937	\$ 901	\$ 499	\$ 360	\$ 1,318	\$ -	\$ 302	\$ 7,345
NORETHISTERONE	\$ 14	\$ 27	\$ 14	\$ 14	\$ 34	\$ -	\$ -	\$ -	\$ 102
NORETHISTERONE + ETHINYLESTRADIOL	\$ 238	\$ 217	\$ 88	\$ 27	\$ 41	\$ 197	\$ -	\$ 14	\$ 821
NORETHISTERONE + MESTRANOL	\$ 14	\$ -	\$ -	\$ -	\$ 15	\$ -	\$ -	\$ -	\$ 29
PRAVASTATIN	\$ 609	\$ 506	\$ 73	\$ 85	\$ 155	\$ 99	\$ -	\$ 173	\$ 1,701
ROSUVASTATIN	\$ 14,703	\$ 10,134	\$ 3,181	\$ 2,143	\$ 2,501	\$ 4,235	\$ 21	\$ 1,678	\$ 38,596
SIMVASTATIN	\$ 2,045	\$ 1,699	\$ 246	\$ 256	\$ 399	\$ 574	\$ -	\$ 518	\$ 5,737
Grand Total	\$ 29,124	\$ 21,263	\$ 6,614	\$ 4,285	\$ 5,461	\$ 8,635	\$ 71	\$ 4,506	\$ 79,960

^ Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 17: Remuneration for Community Pharmacies and Friendly Societies¹ for PBS subsidised prescriptions, 2015-16 to 2018-19
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenditure for PBS and RPBS Prescriptions	2015-16	2016-17	2017-18	2018-19
Price to Pharmacists					
	Ex-Manufacturer Price	\$6,681,787,467	\$7,434,925,412	\$7,091,742,427	\$6,836,700,876
	Wholesale Mark-up	\$381,806,087	\$378,891,056	\$387,784,457	\$388,993,638
	Sub total	\$7,063,593,554	\$7,813,816,468	\$7,479,526,884	\$7,225,694,514
Administration, Handling and Storage Costs					
	AHI fee*	\$851,891,208	\$858,003,695	\$947,464,033	\$968,836,715
	Sub total	\$851,891,208	\$858,003,695	\$947,464,033	\$968,836,715
	*Administration, Handling and Infrastructure fee, formerly known as Pharmacy Mark-up				
Pharmacist's Specialised Skills in Dispensing the Medicines					
	Dispensing Fee	\$1,462,955,398	\$1,446,903,420	\$1,478,908,909	\$1,510,327,061
	Dangerous Drug Fee	\$23,701,624	\$24,846,127	\$25,531,407	\$25,467,071
	Wastage	\$3,002,090	\$3,699,519	\$4,294,784	\$4,553,415
	Container Fee	\$291,774	\$318,322	\$467,256	\$681,930
	Sub total	\$1,489,950,887	\$1,475,767,389	\$1,509,202,356	\$1,541,029,477
Other					
	Premium Free Dispensing Incentive	\$108,707,406	\$122,437,715	\$130,515,164	\$150,062,235
	Electronic Prescription Fee ²	\$9,040,676	\$8,855,832	\$11,495,181	\$12,141,758
	Sub total	\$117,748,082	\$131,293,547	\$142,010,345	\$162,203,992
Total³	\$9,523,183,730	\$10,278,881,099	\$10,078,203,618	\$9,897,764,698	

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	\$6,681,787,467	\$7,434,925,412	\$7,091,742,427	\$6,836,700,876
Wholesale cost	\$381,806,087	\$378,891,056	\$387,784,457	\$388,993,638
Pharmacy cost	\$2,459,590,177	\$2,465,064,631	\$2,598,676,734	\$2,672,070,184
Total	\$9,523,183,730	\$10,278,881,099	\$10,078,203,618	\$9,897,764,698

1. Table 17 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

It does not include:

- * Efficient Funding of Chemotherapy (EFC);
- * hospital PBS claims for s85 items (as the report's focus is on community pharmacy);
- * some private hospital HSD claims; and
- * most public hospital HSD claims.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. The Electronic Prescription Fee (EPF) is listed as a program under 6CPA.

3. Health's 2018-19 Annual Report lists the administered expenses for pharmaceutical benefits as \$11.8 billion. The difference between that figure and the total figure above is attributable to:

- * the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programs, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Program).
- * the annual report data is based on accrual figures, whilst the above data is cash basis;
- * the annual report does not include patient contributions;
- * the annual report data does not include the Premium Free Dispensing Incentive (PFDI) or EPF;
- * the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS, and
- * the annual report also excludes the items in the footnote 1 above.

Table 18: CPA Professional Pharmacy Programs Expenditure, 2018-19

Under the Sixth CPA there were a range of professional programs and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programs under CPA in 2018-19 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$17,958,390
Rural Pharmacy Workforce Program	\$3,388,438
Medication Management services	\$99,778,803
Medication Adherence services	\$92,009,430
Aboriginal & Torres Strait Islander programs	\$5,105,963
Pharmacy Program administration fees	\$13,619,586
Programs Total	\$231,860,610

Notes:

1. For the Programs administration arrangements for 2018-19, the total funding provided to the Pharmacy Programs Administrator was \$231,860,610 (accrual figure). Of this, \$7,910,697 was provided to the Pharmacy Guild and \$5,708,889 to Australian Healthcare Associates for the purpose of Pharmacy Program administration fees. This means the Pharmacy Program administration fees was 5.87% of the total funds.
2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 17 of the report.
3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$80,167
Emergency Locum Service	\$200,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$281,250
Undergraduate Pharmacy-Scholarship Scheme	\$500,000
CPE - Continuing Professional Education Allowance	\$300,777
Pharmacy - Rural Administration Support	\$195,833
Rural Pharmacy - Mentor Scheme	\$20,833
Post Intern Incentive Allowance	\$260,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$800,000
RPLO	\$749,578
Program Total	\$3,388,438

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$41,826,946
Residential Medication Management Review (RMMR)	\$18,558,168
Home Medicines Review (HMR)	\$19,685,088
Clinical Interventions by pharmacists (Pharmacy Practice Incentives)	\$19,708,601
Program Total	\$99,778,803

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids (Pharmacy Practice Incentives)	\$86,207,776
Staged Supply (Pharmacy Practice Incentives)	\$5,801,654
Program Total	\$92,009,430

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$50,000
Workforce (traineeships)	\$160,000
Supporting s100 Remote Aboriginal Area Health Services (RAAHS)	\$2,369,909
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander people (QUMAX)	\$2,526,054
Program Total	\$5,105,963

Table 19: Actual Costs of Major Components of CPA*, 2018-19

Component	Expenditure
Pharmacy remuneration	\$ 2,465,064,631
Wholesale remuneration	\$ 378,891,056
Professional programs	\$ 231,860,610
Community Services Obligation (CSO)	\$ 195,220,000
Total	\$ 3,271,036,297

* The current Community Pharmacy Agreement is the 6th CPA.

Notes:

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programs and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Health receives from the Department of Human Services. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

Table 20: Community Services Obligation (CSO) Expenditure, 2018-19

Component	Expenditure
CSO funding pool	\$ 193,931,345
CSO admin	\$ 1,288,655
Total	\$ 195,220,000

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health.

PBS Information Line Report, 2018-19

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1 July 2018 – 30 June 2019, the information line received **6,390** calls. This was a decrease of 2.19% from the previous financial year, where 6,533 calls were received.

Breakdown of calls by month:

Month	Number of calls
July 2018	530
August 2018	629
September 2018	516
October 2018	686
November 2018	574
December 2018	416
January 2019	590
February 2019	513
March 2019	474
April 2019	463
May 2019	528
June 2019	471
Total	6,390

National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2016 until 30 June 2020.

The NDSS is managed by the Department of Health through the Diabetes Products Section, in the Pharmacy Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin infusion pump consumables, and blood and urine testing strips, and are available through Access Points nationally. Access Points comprise community pharmacies and very small numbers of other entities, such as health centres, hospitals and aged care facilities. Since 1 April 2017, the NDSS has also provided fully subsidised continuous glucose monitoring products to eligible young Australians with Type 1 Diabetes, up to the age of 21 years.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%
2018-19	416,269	3.2%	892,801	2.2%	1,309,070	2.52%

National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2018-19 financial year was over \$183 million. From 2016-17, NDSS Registrant co-payments are now returned to Consolidated Revenue.

PBS Expenditure and Prescriptions 2018-19

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2018-19)

PRESCRIPTIONS	GENERAL	PENSIONER	CONC	S/NET	TOTAL	DRS BAG	TOTAL - ALL PRESCRIPTIONS
1948/49	280,719				280,719		280,719
1949/50	484,210				484,210		484,210
1950/51	3,758,622				3,758,622		3,758,622
1951/52	6,515,668	1,655,570			8,171,238		8,171,238
1952/53	6,853,937	2,766,947			9,620,884		9,620,884
1953/54	7,004,421	3,453,551			10,457,972		10,457,972
1954/55	9,201,387	4,418,633			13,620,020		13,620,020
1955/56	8,970,890	5,235,013			14,205,903		14,205,903
1956/57	9,045,439	5,580,946			14,626,385		14,626,385
1957/58	10,309,446	6,313,214			16,622,660		16,622,660
1958/59	13,253,168	6,821,578			20,074,746		20,074,746
1959/60	16,624,342	8,028,968			24,653,310		24,653,310
1960/61	20,489,065	10,727,570			31,216,635		31,216,635
1961/62	26,050,370	11,664,036			37,714,406		37,714,406
1962/63	29,517,810	12,674,230			42,192,040		42,192,040
1963/64	31,039,624	13,317,273			44,356,897		44,356,897
1964/65	33,714,429	13,841,372			47,555,801		47,555,801
1965/66	35,084,551	14,908,393			49,992,944		49,992,944
1966/67	36,750,907	16,936,435			53,687,342		53,687,342
1967/68	37,053,212	18,369,634			55,422,846		55,422,846
1968/69	40,453,366	19,954,471			60,407,837		60,407,837
1969/70	44,071,198	21,504,166			65,575,364		65,575,364
1970/71	48,971,406	22,515,117			71,486,523		71,486,523
1971/72	48,491,692	23,950,503			72,442,195		72,442,195
1972/73	49,115,497	25,560,576			74,676,073		74,676,073
1973/74	59,499,823	27,788,036			87,287,859		87,287,859
1974/75	67,350,637	30,323,662			97,674,299		97,674,299
1975/76	67,722,534	33,394,757			101,117,291		101,117,291
1976/77	56,099,277	33,606,128			89,705,405		89,705,405
1977/78	57,751,904	35,414,619			93,166,523		93,166,523
1978/79	53,553,036	39,409,489			92,962,525		92,962,525
1979/80	46,624,224	42,450,386			89,074,610		89,074,610
1980/81	47,619,120	46,778,057			94,397,177		94,397,177
1981/82	53,834,648	49,739,756			103,574,404		103,574,404
1982/83	50,078,929	52,529,929	2,931,462		105,540,320		105,540,320
1983/84	41,938,964	56,491,285	9,954,995		108,385,244		108,385,244
1984/85	50,690,275	60,069,806	10,068,817		120,828,898		120,828,898
1985/86	46,334,279	63,191,858	10,315,799		119,841,936		119,841,936
1986/87	28,762,909	64,243,148	9,755,680	2	102,761,737		102,761,737
1987/88	12,339,360	81,041,242	7,520,752	15,059,811	100,901,354		100,901,354
1988/89	14,078,934	78,283,599	8,223,231	11,925,271	100,585,764		100,585,764
1989/90	15,361,517	80,761,310	8,856,241	11,725,474	104,979,068		104,979,068
1990/91	10,608,974	36,868,817	36,588,405	11,675,164	95,741,360	558,899	96,300,259

Notes
 -Dr's Bag prior to 90/91 included in General, from 90/91 included in miscellaneous expenditure
 -For 90/91 Concessional includes 'old' (prior to 1/11/90) prescriptions and 'new' (post 1/11/90) concessional category
 -Exclude under co-payment prescriptions

Safety Net
 Prior to 90/91 S/net for Gen & Concess is included in pensioner. In 90/91 free s/net is in both pensioner and s/net categories

PBS Expenditure and Prescriptions 2018-19

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2018-19) Continued

PRESCRIPTIONS	GENERAL				CONCESSIONAL			TOTAL PRESCRIPTIONS	DRS BAG	TOTAL- ALL PRESCRIPTIONS
	NSN	S/Net 1	S/NET 2	TOTAL	NSN	S/NET	TOTAL			
1991/92	8,266,835	2,340,145	1,092,314	11,699,294	67,331,793	14,428,608	81,760,401	93,459,695	660,459	94,120,154
1992/93	10,260,426	3,917,022	2,800,496	16,977,944	71,756,325	16,757,840	88,514,165	105,492,109	689,508	106,181,617
1993/94	11,451,148	4,259,245	3,087,943	18,798,336	77,536,126	18,003,354	95,539,480	114,337,816	704,227	115,042,043
1994/95	13,491,364	4,695,314	2,072	18,188,750	82,400,588	17,457,008	99,857,596	118,046,346	674,331	118,720,677
1995/96	14,212,731	5,488,957	52	19,701,740	85,604,215	18,898,907	104,503,122	124,204,862	683,420	124,888,282
1996/97	14,709,601	3,082,843	14	17,792,458	85,965,797	19,676,007	105,641,804	123,434,262	665,301	124,099,563
1997/98	14,087,393	3,945,591	17	18,033,001	86,389,807	20,060,505	106,450,312	124,483,313	628,496	125,111,809
1998/99	15,153,975	4,111,091		19,265,066	88,475,327	20,608,073	109,083,400	128,348,466	572,753	128,921,219
1999/00	16,296,703	3,928,760		20,225,463	94,281,872	23,078,282	117,360,154	137,585,617	496,306	138,081,923
2000/01	18,526,141	4,340,364		22,866,505	99,285,160	25,420,114	124,705,274	147,571,779	478,999	148,050,778
2001/02	19,292,104	4,813,038		24,105,142	102,018,211	28,406,603	130,424,814	154,529,956	448,283	154,978,239
2002/03	20,694,131	5,188,492		25,882,623	101,459,056	31,177,491	132,636,547	158,519,170	437,516	158,956,686
2003/04	22,443,338	5,544,618		27,987,956	104,619,866	32,827,303	137,447,169	165,435,125	426,976	165,862,101
2004/05	22,194,451	6,209,302		28,403,753	105,377,946	36,095,311	141,473,257	169,877,010	402,492	170,279,502
2005/06	20,917,523	5,910,828		26,828,351	105,152,486	35,945,690	141,098,176	167,926,527	396,088	168,322,615
2006/07	19,871,669	4,710,422		24,582,091	110,917,202	32,675,864	143,593,066	168,175,157	360,362	168,535,519
2007/08	19,607,454	4,553,340		24,160,794	113,118,234	33,680,813	146,799,047	170,959,841	336,182	171,296,023
2008-09	20,746,777	5,580,636		26,327,413	119,906,347	35,234,371	155,140,718	181,468,131	367,996	181,836,127
2009-10	21,226,750	4,763,435		25,990,185	122,832,364	34,756,644	157,589,008	183,579,193	332,344	183,911,537
2010-11	21,032,398	4,943,233		25,975,631	125,446,923	36,381,986	161,828,909	187,804,540	337,715	188,142,255
2011-12	21,239,413	4,820,643		26,060,056	130,441,952	38,046,697	168,488,649	194,548,705	324,424	194,873,129
2012-13	19,323,589	4,371,046		23,694,635	133,646,630	39,611,994	173,258,624	196,953,259	352,123	197,305,382
2013-14	18,050,307	4,052,529		22,102,836	145,340,393	42,009,011	187,349,404	209,452,240	363,763	209,816,003
2014-15	15,902,515	3,544,902		19,447,417	147,979,717	44,277,679	192,257,396	211,704,813	380,376	212,085,189
2015-16	13,770,978	3,180,897		16,951,875	146,529,394	44,119,861	190,649,255	207,601,130	388,859	207,989,989

New Series	GENERAL			CONCESSIONAL			TOTAL PBS	DRS BAG	MISC and S100	TOTAL - ALL PRESCRIPTIONS
	NSN	S/Net	TOTAL	NSN	S/Net	TOTAL				
2016-17	12,334,542	2,699,345	15,033,887	144,336,986	36,045,418	180,382,404	195,416,291	394,352	2,560,813	198,371,456
2017-18	13,332,423	2,616,813	15,949,236	148,018,925	37,047,645	185,066,570	201,015,806	398,051	2,645,790	204,059,647
2018-19	13,490,749	2,637,491	16,128,240	148,244,490	37,499,894	185,744,384	201,872,624	402,827	2,813,028	205,088,479

CONC: Concessional

S/NET: Safety Net

PENSIONER: Before 1 November 1990 pensioners received PBS drugs free of charge.

NSN: Non Safety Net

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

MISC and SECT 100: Section 100 programs.

Note: From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, prescriptions were reported by the date that they were processed by the Department of Human Services.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2018-19)

GOVERNMENT EXPENDITURE YEAR	-\$					HOSP & MISC	TOTAL GOVT COST	PATIENT CONTRIBUTION		TOTAL	TOTAL COST	TOTAL with
	GEN	CONC	PENS	SAFETY NET	SUB TOTAL			GEN	CON		PRESCRIPTIONS	\$.100 & Misc
1948/49	132,536				132,536	165,538	298,074			-	132,536	298,074
1949/50	346,682				346,682	262,696	609,378			-	346,682	609,378
1950/51	5,453,558				5,453,558	406,768	5,860,326			-	5,453,558	5,860,326
1951/52	13,424,294		715,264		14,139,558	1,230,536	15,370,094			-	14,139,558	15,370,094
1952/53	12,399,568		1,457,316		13,856,884	573,734	14,430,618			-	13,856,884	14,430,618
1953/54	14,320,372		2,021,560		16,341,932	2,116,894	18,458,826			-	16,341,932	18,458,826
1954/55	16,303,940		2,589,672		18,893,612	2,585,322	21,478,934			-	18,893,612	21,478,934
1955/56	18,061,092		3,015,920		21,077,012	2,697,858	23,774,870			-	21,077,012	23,774,870
1956/57	17,171,670		3,586,200		20,757,870	2,675,776	23,433,646			-	20,757,870	23,433,646
1957/58	22,826,484		4,246,490		27,072,974	2,995,004	30,067,978			-	27,072,974	30,067,978
1958/59	33,112,570		5,034,746		38,147,316	3,798,278	41,945,594			-	38,147,316	41,945,594
1959/60	36,714,806		7,148,446		43,863,252	4,808,090	48,671,342	1,890,756		1,890,756	45,754,008	50,562,098
1960/61	34,282,496		14,676,698		48,959,194	6,803,248	55,762,442	10,324,740		10,324,740	59,283,934	66,087,182
1961/62	44,632,488		18,194,996		62,827,484	7,552,282	70,379,766	13,007,776		13,007,776	75,835,260	83,387,542
1962/63	47,093,026		19,830,750		66,923,776	9,986,382	76,910,158	14,742,448		14,742,448	81,666,224	91,652,606
1963/64	46,460,998		20,601,714		67,062,712	11,775,958	78,838,670	15,573,804		15,573,804	82,636,516	94,412,474
1964/65	48,929,748		21,564,420		70,494,168	11,708,442	82,202,610	16,841,354		16,841,354	87,335,522	99,043,964
1965/66	53,078,046		24,071,127		77,149,173	14,634,501	91,783,674	17,481,228		17,481,228	94,630,401	109,264,902
1966/67	56,655,939		29,280,268		85,936,207	15,344,592	101,280,799	18,347,036		18,347,036	104,283,243	119,627,835
1967/68	56,800,249		32,115,335		88,915,584	16,218,859	105,134,443	18,504,345		18,504,345	107,419,929	123,638,788
1968/69	64,024,983		36,609,257		100,634,240	17,739,118	118,373,358	20,129,402		20,129,402	120,763,642	138,502,760
1969/70	73,227,887		41,068,702		114,296,589	22,421,727	136,718,316	21,941,691		21,941,691	136,238,280	158,660,007
1970/71	88,176,385		45,180,856		133,357,241	26,917,666	160,274,907	24,384,028		24,384,028	157,741,269	184,658,935
1971/72	90,061,869		52,005,350		142,067,219	31,201,229	173,268,448	35,466,642		35,466,642	177,533,861	208,735,090
1972/73	87,431,438		58,139,459		145,570,897	32,061,691	177,632,588	48,640,243		48,640,243	194,211,140	226,272,831
1973/74	108,066,351		66,802,821		174,869,172	43,426,672	218,295,844	59,015,335		59,015,335	233,884,507	277,311,179
1974/75	131,341,320		80,586,986		211,928,306	50,368,781	262,297,087	66,827,982		66,827,982	278,756,288	329,125,069
1975/76	149,033,245		107,317,318		256,350,563	27,490,706	283,841,269	95,244,660		95,244,660	351,595,223	379,085,929
1976/77	111,077,507		115,201,775		226,279,282	8,623,582	234,902,864	111,676,421		111,676,421	337,955,703	346,579,285
1977/78	118,303,375		127,911,837		246,215,212	9,832,410	256,047,622	115,025,169		115,025,169	361,240,381	371,072,791
1978/79	110,425,438		151,125,681		261,551,119	9,767,502	271,318,621	129,540,759		129,540,759	391,091,878	400,859,380
1979/80	101,185,503		166,361,113		267,546,616	7,088,452	274,635,068	123,418,168		123,418,168	390,964,784	398,053,236
1980/81	107,903,558		191,043,798		298,947,356	10,267,063	309,214,419	129,923,272		129,923,272	428,870,628	439,137,691
1981/82	139,547,856		239,894,493		379,442,349	11,377,241	390,819,590	157,957,635		157,957,635	537,399,984	548,777,225
1982/83	131,773,044	11,100,973	272,707,495		415,581,512	14,685,428	430,266,940	170,617,530	5,882,844	176,500,374	592,081,886	606,767,314
1983/84	114,638,367	39,276,732	317,819,660		471,734,759	17,490,165	489,224,924	166,043,447	19,975,026	186,018,473	657,753,232	675,243,397
1984/85	142,439,672	43,266,712	356,213,948		541,920,332	17,877,162	559,797,494	201,142,242	20,208,116	221,350,358	763,270,690	781,147,852
1985/86	138,365,148	50,172,930	408,026,507		596,564,585	19,258,116	615,822,701	222,286,396	20,715,057	243,001,453	839,566,038	858,824,154
1986/87	140,571,611	59,738,152	514,236,037	12	714,545,800	23,457,302	738,003,102	167,130,307	22,048,299	189,178,606	903,724,406	927,181,708
1987/88	111,740,361	51,574,897	747,536,316	159,418,168	910,851,574	35,612,019	946,463,593	117,938,301	18,839,286	136,777,587	1,047,629,161	1,083,241,180
1988/89	132,040,607	63,272,252	795,027,196	138,531,290	990,340,055	33,194,842	1,023,534,897	147,704,171	20,603,194	168,307,365	1,158,647,420	1,191,842,262
1989/90	170,039,203	74,757,555	890,753,297	150,064,548	1,135,550,055	43,852,385	1,179,402,440	162,587,554	22,174,539	184,762,093	1,320,312,148	1,364,164,533
1990/91	157,783,001	342,720,328	428,743,821	580,709,870	1,094,463,443	64,798,247	1,159,261,690	132,120,868	91,672,986	223,793,854	1,318,257,297	1,383,055,544

Note -Free Pensioner category removed from 1 Nov 90, \$2.50 copayment and free safety net introduced for all Concessionals
 -Dr's Bag prior to 90/91 included in General from 90/91 (\$12,255,895) included in Misc
Safety Net -For Gen & Conc prior to 90/91 is included in Pensioner
 -For 90/91 S/net includes both pre & post 1/11/90 free Snet
 -Gen S/net 1 included in Concess in 90/91
 -Gen S/net 2 (free) 1 Jan 91 to 31 Dec 93

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2018-19) Continued

GOVERNMENT EXPENDITURE - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
1991/92	160,765,548	36,400,482	18,911,584	216,077,614	708,413,833	195,000,082	903,413,915	1,119,491,529	100,877,826	1,220,369,355	
1992/93	188,270,160	65,845,466	53,077,875	307,193,500	844,972,301	251,249,539	1,096,221,840	1,403,415,340	101,552,426	1,504,967,766	
1993/94	224,675,364	78,832,510	63,861,452	367,369,326	1,019,651,580	297,597,894	1,317,249,474	1,684,618,800	116,696,888	1,801,315,688	
1994/95	290,765,883	93,406,668	38,565	384,211,116	1,194,999,580	302,502,892	1,497,502,472	1,881,713,588	109,621,215	1,991,334,803	
1995/96	343,025,066	118,655,085	785	461,680,936	1,369,432,585	360,130,508	1,729,563,093	2,191,244,029	135,473,133	2,326,717,162	
1996/97	392,246,135	72,831,781	210	465,078,126	1,465,657,637	401,814,359	1,867,471,996	2,332,550,122	205,545,012	2,538,095,134	
1997/98	411,856,192	98,613,376	465	510,470,033	1,576,058,096	439,989,321	2,016,047,417	2,526,517,450	258,950,240	2,785,467,690	
1998/99	469,042,094	106,618,491	-	575,660,585	1,739,535,268	467,079,112	2,206,614,380	2,782,274,965	287,469,135	3,069,744,100	
1999/00	521,018,128	107,012,848	-	628,030,976	2,000,636,597	547,829,734	2,548,466,331	3,176,497,307	311,727,262	3,488,224,569	
2000/01	662,099,200	128,173,886	-	790,273,086	2,359,650,038	660,303,947	3,019,953,985	3,810,227,071	347,901,802	4,158,128,873	
2001/02	691,204,687	148,498,520	-	839,703,207	2,569,555,585	778,411,796	3,347,967,381	4,187,670,588	396,386,682	4,584,057,270	
PATIENT CONTRIBUTION - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
1991/92	128,988,053	6,043,066	-	135,031,119	173,201,117	-	173,201,117	308,232,236	1,427,723,765	100,877,826	1,528,601,591
1992/93	162,967,769	10,202,578	-	173,170,347	186,726,902	-	186,726,902	359,897,249	1,763,312,589	101,552,426	1,864,865,015
1993/94	183,012,475	11,074,025	-	194,086,500	201,596,301	-	201,596,301	395,682,801	2,080,301,601	116,696,888	2,196,998,489
1994/95	218,094,751	12,207,816	-	230,302,567	214,241,512	-	214,241,512	444,544,079	2,326,257,667	109,621,215	2,435,878,882
1995/96	237,239,817	14,278,699	-	251,518,516	226,583,554	-	226,583,554	478,102,070	2,669,346,099	135,473,133	2,804,819,232
1996/97	269,715,066	8,375,980	-	278,091,046	252,104,590	-	252,104,590	530,195,636	2,862,745,758	205,545,012	3,068,290,770
1997/98	281,739,252	12,625,016	-	294,364,268	276,440,026	-	276,440,026	570,804,294	3,097,321,744	258,950,240	3,356,271,984
1998/99	305,064,052	13,155,417	-	318,219,469	283,117,963	-	283,117,963	601,337,432	3,383,612,397	287,469,135	3,671,081,532
1999/00	333,003,549	12,584,337	-	345,587,886	306,183,001	-	306,183,001	651,770,887	3,828,268,194	311,727,262	4,139,995,456
2000/01	392,432,536	14,353,837	-	406,786,373	337,379,028	-	337,379,028	744,165,401	4,554,392,472	347,901,802	4,902,294,274
2001/02	426,974,621	16,864,336	-	443,838,957	362,237,529	-	362,237,529	806,076,486	4,993,747,074	396,386,682	5,390,133,756
DOCTOR'S BAG - \$ - (included in miscellaneous from 90/91)											
1990/91	12,255,895	-	-	-	-	-	-	-	-	-	-
1991/92	14,514,725	-	-	-	-	-	-	-	-	-	-
1992/93	16,082,655	-	-	-	-	-	-	-	-	-	-
1993/94	16,679,933	-	-	-	-	-	-	-	-	-	-
1994/95	15,674,643	-	-	-	-	-	-	-	-	-	-
1995/96	16,202,098	-	-	-	-	-	-	-	-	-	-
1996/97	15,769,173	-	-	-	-	-	-	-	-	-	-
1997/98	14,953,823	-	-	-	-	-	-	-	-	-	-
1998/99	13,370,491	-	-	-	-	-	-	-	-	-	-
1999/00	10,754,395	-	-	-	-	-	-	-	-	-	-
2000/01	10,343,534	-	-	-	-	-	-	-	-	-	-
2001/02	9,803,682	-	-	-	-	-	-	-	-	-	-

note- from 91/92 all figures are sourced from the Department of Human Services (DHS) processing where available -miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional
S/Net: Safety Net
GEN: General
NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.
HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.
PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2018-19) Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2002/03	\$747,049,026	\$169,693,390	\$916,742,416	\$2,741,874,040	\$907,119,434	\$3,648,993,474	\$4,565,735,890	\$477,352,298	\$5,043,088,188	
2003/04	\$824,130,608	\$190,682,979	\$1,014,813,587	\$2,972,331,634	\$1,004,522,779	\$3,976,854,413	\$4,991,668,000	\$570,500,000	\$5,562,168,000	
2004/05	\$850,690,906	\$222,668,220	\$1,073,359,125	\$3,077,033,801	\$1,145,497,231	\$4,222,531,032	\$5,295,890,157	\$668,500,000	\$5,964,390,157	
2005/06	\$850,095,680	\$216,246,563	\$1,066,342,242	\$3,145,480,431	\$1,172,502,111	\$4,317,982,542	\$5,384,324,784	\$764,000,000	\$6,148,324,784	
2006/07	\$890,275,536	\$174,127,771	\$1,064,403,307	\$3,333,875,949	\$1,067,478,074	\$4,401,354,023	\$5,465,757,330	\$886,500,000	\$6,352,257,330	
2007/08	\$1,039,451,749	\$173,499,550	\$1,212,951,299	\$3,561,294,283	\$1,137,925,393	\$4,699,219,676	\$5,912,170,974	\$975,500,000	\$6,887,670,974	
2008/09	\$1,220,279,806	\$217,487,483	\$1,437,767,290	\$3,909,584,010	\$1,216,050,241	\$5,125,634,250	\$6,563,401,540	\$1,081,400,000	\$7,644,801,540	
2009/10	\$1,339,182,210	\$199,599,002	\$1,538,781,212	\$4,220,391,341	\$1,259,719,602	\$5,480,110,943	\$7,018,892,155	\$1,232,400,000	\$8,251,292,155	
2010-11	\$1,412,781,352	\$211,944,918	\$1,624,726,270	\$4,367,739,898	\$1,330,682,636	\$5,698,422,533	\$7,323,148,803	\$1,335,500,000	\$8,658,648,803	
2011-12	\$1,453,773,280	\$208,167,009	\$1,661,940,288	\$4,476,104,435	\$1,390,159,396	\$5,866,263,831	\$7,528,204,119	\$1,473,700,000	\$9,001,904,119	
2012-13	\$1,339,654,102	\$169,213,844	\$1,508,867,945	\$4,209,086,581	\$1,351,536,398	\$5,560,622,979	\$7,069,490,924	\$1,812,600,000	\$8,882,090,924	
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2002/03	\$470,306,937	\$18,698,099	\$489,005,036	\$370,426,183	-	\$370,426,183	\$859,431,219	\$5,425,167,109	\$477,352,298	\$5,902,519,407
2003/04	\$524,763,848	\$20,538,514	\$545,302,362	\$392,513,143	-	\$392,513,143	\$937,815,505	\$5,929,483,505	\$570,500,000	\$6,499,983,505
2004/05	\$572,963,103	\$23,742,733	\$596,705,836	\$443,930,641	-	\$443,930,641	\$1,040,636,477	\$6,336,526,634	\$668,500,000	\$7,005,026,634
2005/06	\$606,897,345	\$27,199,070	\$634,096,415	\$489,173,277	-	\$489,173,277	\$1,123,269,692	\$6,507,594,476	\$764,000,000	\$7,271,594,476
2006/07	\$596,483,266	\$22,154,622	\$618,637,888	\$532,682,972	-	\$532,682,972	\$1,151,320,859	\$6,617,078,189	\$886,500,000	\$7,503,578,189
2007/08	\$607,183,393	\$22,323,024	\$629,506,417	\$559,962,883	-	\$559,962,883	\$1,189,469,300	\$7,101,640,274	\$975,500,000	\$8,077,140,274
2008/09	\$663,449,571	\$27,928,829	\$691,378,400	\$617,378,323	-	\$617,378,323	\$1,308,756,723	\$7,872,158,263	\$1,081,400,000	\$8,953,558,263
2009/10	\$701,961,714	\$25,253,391	\$727,215,106	\$656,949,638	-	\$656,949,638	\$1,384,164,743	\$8,403,056,898	\$1,232,400,000	\$9,635,456,898
2010-11	\$707,968,006	\$26,706,262	\$734,674,267	\$689,108,592	-	\$689,108,592	\$1,423,782,860	\$8,746,931,663	\$1,335,500,000	\$10,082,431,663
2011-12	\$735,994,339	\$27,003,502	\$762,997,841	\$742,139,779	-	\$742,139,779	\$1,505,137,620	\$9,033,341,739	\$1,473,700,000	\$10,507,041,739
2012-13	\$689,036,554	\$25,352,649	\$714,389,203	\$781,002,893	-	\$781,002,893	\$1,495,392,096	\$8,564,883,021	\$1,812,600,000	\$10,377,483,021
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2002/03	\$9,510,606									
2003/04	\$9,408,669									
2004/05	\$9,365,803									
2005/06	\$10,063,803									
2006/07	\$10,698,205									
2007/08	\$13,468,779									
2008/09	\$14,533,302									
2009/10	\$13,571,776									
2010-11	\$14,228,520									
2011-12	\$12,974,506									
2012-13	\$14,755,085									

note- from 91/92 all figures are sourced from the Department of Human Services (DHS) processing where available
-miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Pharmaceutical Benefits Scheme History - Government Expenditure & Patient Contribution, 1948-49 to 2018-19 Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2013-14	\$1,429,860,300	\$154,692,449	\$1,584,552,749	\$4,319,414,670	\$1,388,583,542	\$5,707,998,212	\$7,292,550,961	\$2,033,900,000	\$9,326,450,961	
2014-15	\$1,463,256,600	\$129,523,975	\$1,592,780,575	\$4,123,482,128	\$1,380,416,342	\$5,503,898,470	\$7,096,679,044	\$2,183,101,118	\$9,279,780,162	
2015-16	\$1,785,357,915	\$118,821,879	\$1,904,179,793	\$4,630,980,302	\$1,413,858,158	\$6,044,838,460	\$7,949,018,254	\$2,752,825,107	\$10,701,843,361	
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	DRS BAG	MISC and S100	TOTAL GOVT EXP
2016-17	\$2,088,188,915	\$103,984,977	\$2,192,173,892	\$5,315,606,905	\$1,204,716,252	\$6,520,323,157	\$8,712,497,049	\$16,718,674	\$3,043,936,194	\$11,773,151,917
2017-18	\$1,981,594,072	\$101,429,150	\$2,083,023,223	\$5,127,198,161	\$1,236,961,876	\$6,364,160,037	\$8,447,183,260	\$16,568,617	\$3,139,112,049	\$11,602,863,926
2018-19	\$2,005,253,340	\$102,355,665	\$2,107,609,004	\$4,844,366,564	\$1,243,669,704	\$6,088,036,267	\$8,195,645,272	\$16,002,440	\$3,487,069,944	\$11,698,717,656
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2013-14	\$656,913,329	\$23,915,012	\$680,828,341	\$864,226,399	-	\$864,226,399	\$1,545,054,740	\$8,837,605,701	\$2,033,900,000	\$10,871,505,701
2014-15	\$567,399,905	\$21,021,090	\$588,420,995	\$877,483,279	-	\$877,483,279	\$1,465,904,274	\$8,562,583,318	\$2,183,101,118	\$10,745,684,436
2015-16	\$494,124,051	\$19,115,443	\$513,239,494	\$880,965,644	-	\$880,965,644	\$1,394,205,138	\$9,343,223,391	\$2,752,825,107	\$12,096,048,498
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	TOTAL COST *	MISC and S100	TOTAL EXP **
2016-17	\$444,029,285	\$16,448,625	\$460,477,909	\$880,418,081	-	\$880,418,081	\$1,340,895,990	\$10,053,393,039	\$38,361,124	\$13,152,409,031
2017-18	\$484,120,874	\$16,143,997	\$500,264,871	\$915,055,636	-	\$915,055,636	\$1,415,320,507	\$9,862,503,767	\$40,183,135	\$13,058,367,568
2018-19	\$494,513,005	\$16,477,196	\$510,990,200	\$929,032,414	-	\$929,032,414	\$1,440,022,615	\$9,635,667,887	\$44,642,304	\$13,183,382,575
TOTAL COST *	Total cost for Section 85 (Patient payment + Government benefit)									
TOTAL EXP **	Total PBS Expenditure, Section 85, Section 100 and Drs Bag (Patient payment + Government benefit)									
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2013-14	\$16,009,408									
2014-15	\$16,340,036									
2015-16	\$15,887,150									
2016-17	\$16,718,674									
2017-18	\$16,568,617									
2018-19	\$16,002,440									

Notes:

From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, Government expenditure and patient contributions were reported by the date that the prescriptions were processed by the Department of Human Services.
 From 1991-92 all figures are sourced from the Department of Human Services (DHS) processing where available
 Miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Section 100 programs, other ungrouped expenditure

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.